<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Materials (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Materials (Basel)</journal-id><journal-id journal-id-type="publisher-id">materials</journal-id><journal-title-group><journal-title>Materials</journal-title></journal-title-group><issn pub-type="epub">1996-1944</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7727669</article-id><article-id pub-id-type="pmid">33255252</article-id><article-id pub-id-type="doi">10.3390/ma13235312</article-id><article-id pub-id-type="publisher-id">materials-13-05312</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9666-2134</contrib-id><name><surname>&#x00141;akomska</surname><given-names>Iwona</given-names></name><xref ref-type="aff" rid="af1-materials-13-05312">1</xref><xref rid="c1-materials-13-05312" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>&#x0015a;mi&#x00142;owicz</surname><given-names>Dariusz</given-names></name><xref ref-type="aff" rid="af2-materials-13-05312">2</xref></contrib><contrib contrib-type="author"><name><surname>Jakubowski</surname><given-names>Mateusz</given-names></name><xref ref-type="aff" rid="af1-materials-13-05312">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9962-6024</contrib-id><name><surname>Sitkowski</surname><given-names>Jerzy</given-names></name><xref ref-type="aff" rid="af3-materials-13-05312">3</xref><xref ref-type="aff" rid="af4-materials-13-05312">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8801-7728</contrib-id><name><surname>Wojtczak</surname><given-names>Andrzej</given-names></name><xref ref-type="aff" rid="af1-materials-13-05312">1</xref></contrib></contrib-group><aff id="af1-materials-13-05312"><label>1</label>Faculty of Chemistry, Nicolaus Copernicus University in Toru&#x00144;, Gagarina 7, 87-100 Toru&#x00144;, Poland; <email>mjakubowski@umk.pl</email> (M.J.); <email>awojt@chem.umk.pl</email> (A.W.)</aff><aff id="af2-materials-13-05312"><label>2</label>Inorganic Chemistry I&#x02014;Bioinorganic Chemistry, Ruhr-University Bochum, Universit&#x000e4;tsstra&#x000df;e 150, 44801 Bochum, Germany; <email>dariusz.smilowicz@rub.de</email></aff><aff id="af3-materials-13-05312"><label>3</label>Institute of Organic Chemistry, Polish Academic of Science, Kasprzaka 44/52, 01-224 Warszawa, Poland; <email>j.sitkowski@nil.gov.pl</email></aff><aff id="af4-materials-13-05312"><label>4</label>National Medicines Institute, Che&#x00142;mska 30/34, 00-725 Warszawa, Poland</aff><author-notes><corresp id="c1-materials-13-05312"><label>*</label>Correspondence: <email>iwolak@chem.umk.pl</email>; Tel.: +48-56-611-4510</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2020</year></pub-date><volume>13</volume><issue>23</issue><elocation-id>5312</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Herein, we present dicarboxylate platinum(II) complexes of the general formula [Pt(mal)(DMSO)(L)] and [Pt(CBDC)(DMSO)(L)], where L is dbtp 5,7-di<italic>tertb</italic>utyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine) or ibmtp (7-isobutyl-5-methyl-1,2,4- triazolo[1,5-<italic>a</italic>]pyrimidine), as prospective prodrugs. The platinum(II) complexes were synthesized in a one-pot reaction between <italic>cis</italic>-[PtCl<sub>2</sub>(DMSO)<sub>2</sub>], silver malonate or silver cyclobutane-1,1-dicarboxylate and triazolopyrimidines. All platinum(II) compounds were characterized by FT-IR, and <sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N and <sup>195</sup>Pt NMR; and their square planar geometries with one monodentate N(3)-bonded 5,7-disubstituted-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine, one S-bonded molecule of dimethyl sulfoxide and one O,O-chelating malonato (<bold>1</bold>, <bold>2</bold>) or O,O-chelating cyclobutane-1,1-dicarboxylato (<bold>3</bold>, <bold>4</bold>) was determined. Additionally, [Pt(CBDC)(dbtp)(DMSO)] (<bold>3</bold>) exhibited (i) substantial in vitro cytotoxicity against the lung adenocarcinoma epithelial cell line (A549) (IC<sub>50</sub> = 5.00 &#x000b5;M) and the cisplatin-resistant human ductal breast epithelial tumor cell line (T47D) (IC<sub>50</sub> = 6.60 &#x000b5;M); and (ii) definitely exhibited low toxicity against normal murine embryonic fibroblast cells (BALB/3T3).</p></abstract><kwd-group><kwd>platinum(II) complexes</kwd><kwd>dicarboxylato ligands</kwd><kwd>triazolopyrimidines</kwd><kwd>multinuclear NMR</kwd><kwd>lipophilicity</kwd><kwd>in vitro cytotoxicity</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-materials-13-05312"><title>1. Introduction</title><p>Inert square planar Pt(II) drugs currently used in the chemotherapy of some cancers suffer from lack of selectivity, toxicity and poor aqueous solubility, and in many cases acquired or inherent resistance also develops during treatments [<xref rid="B1-materials-13-05312" ref-type="bibr">1</xref>,<xref rid="B2-materials-13-05312" ref-type="bibr">2</xref>,<xref rid="B3-materials-13-05312" ref-type="bibr">3</xref>,<xref rid="B4-materials-13-05312" ref-type="bibr">4</xref>,<xref rid="B5-materials-13-05312" ref-type="bibr">5</xref>,<xref rid="B6-materials-13-05312" ref-type="bibr">6</xref>,<xref rid="B7-materials-13-05312" ref-type="bibr">7</xref>]. To overcome these drawbacks, there is an urgent need to find more selective and low-concentration but effective metal-based chemotherapeutics with improved pharmacological properties [<xref rid="B8-materials-13-05312" ref-type="bibr">8</xref>,<xref rid="B9-materials-13-05312" ref-type="bibr">9</xref>,<xref rid="B10-materials-13-05312" ref-type="bibr">10</xref>] and far fewer side effects than those of current drugs. These new strategies are currently in progress and often take advantage of the differences between healthy and cancer cells [<xref rid="B11-materials-13-05312" ref-type="bibr">11</xref>].</p><p>The main approach in the rational design of platinum(II) complexes focuses on modifications in either the carrier or the leaving ligands [<xref rid="B12-materials-13-05312" ref-type="bibr">12</xref>,<xref rid="B13-materials-13-05312" ref-type="bibr">13</xref>,<xref rid="B14-materials-13-05312" ref-type="bibr">14</xref>]. It is well known that the presence of the dicarboxylato moiety in the coordination sphere enhances the aqueous solubility of platinum(II) complexes [<xref rid="B15-materials-13-05312" ref-type="bibr">15</xref>], reduces side effects and increases the efficiency of platinum(II) anticancer drugs [<xref rid="B16-materials-13-05312" ref-type="bibr">16</xref>,<xref rid="B17-materials-13-05312" ref-type="bibr">17</xref>,<xref rid="B18-materials-13-05312" ref-type="bibr">18</xref>], and does not affect the mechanism of activation and interaction with DNA bases [<xref rid="B19-materials-13-05312" ref-type="bibr">19</xref>]. Dicarboxylato often undergoes chelation, producing five- or six-membered rings with platinum(II) ions, which improves complex stability compared to those of chloride analogues and decreases the interactions with sulfur-containing molecules, such as glutathione, methionine and cysteine, in the bloodstream.</p><p>Currently, attention has been focused on the synthesis of complexes with aromatic N-donor molecules as carrier ligands. Dicarboxylato platinum(II) compounds with heterocyclic derivatives are of interest due to their antiproliferative activity and may represent a new class of promising anticancer prodrugs. Recently, oxalate platinum(II) complexes involving 7-azaindole halogeno-derivatives (nHaza), namely, [Pt(ox)(3ClHaza)<sub>2</sub>] and [Pt(ox)(3BrHaza)<sub>2</sub>], where 3ClHaza symbolizes 3-chloro-7-azaindole and 3BrHaza symbolizes 3-bromo-7-azaindole, have been synthesized [<xref rid="B20-materials-13-05312" ref-type="bibr">20</xref>]. Other oxalate platinum(II) complexes contain derivatives of the plant hormone kinetin (N6-furfuryladenine), namely, [Pt(ox)(L<sub>1</sub>)] and [Pt(ox)(L<sub>2</sub>)], where L<sub>1</sub>-2-chloro-N6-furfuryl-9-isopropyladenine and L<sub>2</sub>-2-chloro-N6-(5-methylfurfuryl)- 9-isopropyladenine [<xref rid="B21-materials-13-05312" ref-type="bibr">21</xref>]. Additionally, our previous initial in vitro antiproliferative activity tests proved that symmetric malonato platinum(II) complexes of the general formula [Pt(mal)(L)<sub>2</sub>], where L is 7-isobutyl-5-methyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine (ibmtp) and 5,7-di<italic>tert</italic>butyl- 1,2,4-triazolo-[1,5-<italic>a</italic>]pyrimidine (dbtp), exhibit excellent in vitro activity against the cisplatin-resistant human ductal breast epithelial tumor cell line (T47D) and against a lung adenocarcinoma epithelial cell line (A549). In vitro antiproliferative studies showed that symmetrical [Pt(mal)(ibmtp)<sub>2</sub>] (3.44 &#x000b5;M) and [Pt(mal)(dbtp)<sub>2</sub>] (2.66 &#x000b5;M) complexes exhibit higher in vitro activity against T47D and A549 cell lines than cisplatin [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>]. These results are greatly promising, but their toxic activity against normal cells blocked their medical application. Therefore, researchers have tried to solve this problem by modifying the coordination sphere via replacement of one N-donor ligand with a dimethyl sulfoxide molecule.</p><p>Among the mixed platinum(II) combinations of the PtO<sub>2</sub>NS type presented in the literature, only two cyclobutane-1,1-dicarboxylic platinum(II) complexes with an S-donor DMSO molecule and an N-donor molecule, namely, E-1-(9-anthryl)-3-(2-pyridyl)-2-propenone ligand (A9pyp) [<xref rid="B23-materials-13-05312" ref-type="bibr">23</xref>] and N6-2-methoxybenzylamino-2-chloro-9-isopropylpurine (mbip) [<xref rid="B24-materials-13-05312" ref-type="bibr">24</xref>], have been presented. The compound [Pt(CBDC)(DMSO)(mbip)] was a by-product of the synthesis of [Pt(CBDC)(mbip)<sub>2</sub>]; therefore, the authors focused only on the structural aspects of the reaction by-product. On the other hand, information on the therapeutic potential of [Pt(CBDC)(A9pyp)(DMSO)] is broader and concerns (i) cytotoxicity against CDDP-sensitive and cisplatin-resistant human ovarian cancer lines (A2780 and A2780R); (ii) intracellular accumulation; and (iii) the ability to interact with DNA. Cytotoxic studies against human ovarian carcinoma cell lines resistant to cisplatin (A2780R) revealed excellent results. The novel [Pt(CBDC)(A9pyp)(DMSO)] complex exhibits higher in vitro activity (3.2 &#x000b5;M) than that of cisplatin (20.4 &#x000b5;M). The authors stated that the presence of a less labile leaving group helps to overcome cisplatin resistance in A2780R cells. Following that line of research, we decided to design low-toxicity and effective platinum-based anticancer prodrugs with triazolopyrimidine. We obtained the four complexes [Pt(mal)(DMSO)(dmtp)], [Pt(CBDC)(DMSO)(dmtp)], [Pt(mal)(DMSO)(dptp)] and [Pt(CBDC)(DMSO)(dptp)], where dmtp is 5,7-dimethyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine and dptp is 5,7-diphenyl-1,2,4- triazolo[1,5-<italic>a</italic>]pyrimidine. Finally, we found that the lipophilic platinum(II) complex with the bulky 5,7-diphenyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine ligand, i.e., ([Pt(mal)(DMSO)(dptp)], displayed 10&#x02011;times lower in vitro toxicity than that of cisplatin against a normal cell line (BALB/3T3) and anticancer activity comparable to that of cisplatin, and indicated an in vitro cytotoxic activity against non-small cell lung carcinoma (A549) similar to that of cisplatin [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>].</p><p>To continue our investigation of dicarboxylato platinum(II) compounds as potential anticancer agents, especially novel mixed platinum(II) complexes containing aromatic N-donor molecules and S-donor ligands as carrier groups (vide supra), we applied 7-isobutyl-5-methyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine (ibmtp) and 5,7-di<italic>tert</italic>butyl-1,2,4-triazolo- [1,5-<italic>a</italic>]pyrimidine (dbtp) to prepare two new malonato platinum(II) complexes with one S-donor DMSO ligand as a non-leaving group, namely, [Pt(mal)(dbtp)(DMSO)] and [Pt(mal)(DMSO)(ibmtp)]. Additionally, we synthesized analogues to the above-mentioned complexes with cyclobutane-1,1-dicarboxylato as the leaving ligand, namely, [Pt(CBDC)(dbtp)(DMSO)] and [Pt(CBDC)(DMSO)(ibmtp)]. In the next step, novel platinum(II) complexes were comprehensively characterized by different spectroscopic methods (IR; <sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N, <sup>195</sup>Pt NMR), and the partition coefficients by the well-known shake-flask method were investigated. Moreover, we determined the in vitro antiproliferative activity and estimated the structure&#x02013;lipophilicity relationship.</p></sec><sec id="sec2-materials-13-05312"><title>2. Materials and Methods</title><sec id="sec2dot1-materials-13-05312"><title>2.1. Instrumentation and Analyses</title><p>The C, H and N contents were determined using a CHN elemental analyzer, Vario Macro Elementary GMBH (Elementar Analysensysteme GMBH, Langenselbold, Germany). The IR spectra were measured on a PerkinElmer Spectrum 2000 FTIR spectrometer (PerkinElmer, Waltham, MA, USA) using KBr (400&#x02013;4000 cm<sup>&#x02212;1</sup>). The UV&#x02013;Vis measurements for the determination of lipophilicity were obtained on a UVD-2950 UV&#x02013;Vis spectrophotometer (Labomed, Los Angeles, CA, USA) using 1.0 cm pathlength quartz cuvettes (1.5 mL).</p><p>The NMR spectra were recorded at RT in DMF-d<sub>7</sub> solutions with a Varian INOVA 500 (Varian Inc., Palo Alto, CA, USA) spectrometer operated at 499.8, 125.7, 50.6 and 107.4 MHz for <sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N and <sup>195</sup>Pt, respectively. The reference standards were TMS for <sup>1</sup>H and <sup>13</sup>C, CH<sub>3</sub>NO<sub>2</sub> for <sup>15</sup>N and K<sub>2</sub>PtCl<sub>6</sub> for <sup>195</sup>Pt. Gradient-enhanced IMPACT-HMBC <sup>1</sup>H-(<sup>15</sup>N) correlation spectra [<xref rid="B26-materials-13-05312" ref-type="bibr">26</xref>] were optimized for a coupling constant of 6 Hz with the following experimental conditions: an acquisition time of 0.2 s, spectral windows of 6000 (F2) and 10,000 (F1) Hz, 1K complex data points, 256 time increments, 30 ms WURST-2 mixing sequence centered within a 60 ms preparation interval (ASAP<sup>2</sup>) and a 150&#x000b0; Ernst angle as the excitation pulse [<xref rid="B27-materials-13-05312" ref-type="bibr">27</xref>].</p></sec><sec id="sec2dot2-materials-13-05312"><title>2.2. Reactants and Methods</title><p>K<sub>2</sub>PtCl<sub>4</sub>, 3-amino-1,2,4-triazole (98%), 6-methyl-2,4-heptanedione (99%), 2,2,6,6-tetramethyl-3,5-heptanedione (98%), malonic acid and cyclobutane-1,1-dicarboxlic acid were purchased from Sigma Aldrich (Merck, St. Louis, MO, USA), whereas inorganic salts and solvents of analytical grade were purchased from Avantor Performance Materials Poland S.A (Gliwice, Poland).</p><p>5,7-Disubstituted derivatives of 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidines were prepared according to the B&#x000fc;low and Haas method by the reaction of 3-amino-1,2,4-triazolewith 6-methyl-2,4-heptanedione for ibmtp and 2,2,6,6-tetramethyl-3,5-heptanedione for dbtp [<xref rid="B28-materials-13-05312" ref-type="bibr">28</xref>]. Disilver malonate (Ag<sub>2</sub>C<sub>3</sub>H<sub>2</sub>O<sub>4</sub>) and disilver cyclobutane-1,1-dicarboxylate (Ag<sub>2</sub>C<sub>6</sub>H<sub>6</sub>O<sub>4</sub>) were prepared by the reaction of AgNO<sub>3</sub> with malonic or cyclobutane-1,1-dicarboxylic acid by a known method [<xref rid="B29-materials-13-05312" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot3-materials-13-05312"><title>2.3. Preparation of Dicarboxylato Platinum(II) Complexes</title><p>The <italic>cis</italic>-[PtCl<sub>2</sub>(DMSO)<sub>2</sub>] used as a substrate for syntheses of complexes (<bold>1</bold>) [Pt(mal)(DMSO)(dbtp)], (<bold>2</bold>) [Pt(mal)(DMSO)(ibmtp)], (<bold>3</bold>) [Pt(CBDC)(DMSO)(dbtp), (<bold>4</bold>) [Pt(CBDC)(DMSO)(ibmtp)] and (<bold>5</bold>) [Pt(mal)(DMSO)(dmtp)] was prepared from K<sub>2</sub>PtCl<sub>4</sub> by the known method [<xref rid="B30-materials-13-05312" ref-type="bibr">30</xref>]. The procedure of the multistep synthesis of platinum(II) complexes (<bold>1</bold>&#x02013;<bold>5</bold>) is depicted in <xref ref-type="fig" rid="materials-13-05312-f001">Figure 1</xref> and described in detail as follows.</p><p>[Pt(mal)(DMSO)(dbtp)] (<bold>1</bold>). A solution of <italic>cis</italic>-[PtCl<sub>2</sub>(DMSO)<sub>2</sub>] (0.0511 g; 0.1210 mmol) in 25 mL of a 1.5:1 (<italic>v</italic>/<italic>v</italic>) mixture of ethanol and water was treated with an equivalent of silver(I) malonato (0.0365 g; 0.1147 mmol). The reaction mixture was stirred in the dark at room temperature for 48 h. Then, an equivalent of dbtp (0.0254 g; 0.1093 mmol) was added to the resulting <italic>cis</italic>-[Pt(mal)(DMSO)<sub>2</sub>] solution. The reaction mixture was further stirred under the same conditions for the next 48 h. The AgCl precipitate was removed by centrifugation and filtration. Slow evaporation of the solvent gave a pale-yellow precipitate, which was washed with acetone and diethyl ether and dried under vacuum. The (<bold>2</bold>&#x02013;<bold>4</bold>) platinum(II) complexes were prepared exactly in the same way.</p><p>(<bold>1</bold>) (Dimethylsulfoxide-&#x003ba;S)(5,7-di<italic>tert</italic>butyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine-&#x003ba;N(3))(malonato-&#x003ba;<sup>2</sup>O,O&#x02032;) platinum(II)</p><p>Yield: 0.0527 g (76.02%). <sup>1</sup>H NMR (499.8 MHz, dmf-d<sub>7</sub>): &#x003b4; = 3.51 (s, 6H, 2 &#x000d7; CH<sub>3</sub>(dmso)), 3.56 (s, 2H, CH<sub>2</sub>(mal)), 7.55 (s, H, H6), 9.19 ppm (s, H, H2); <sup>13</sup>C NMR (125.7 MHz, dmf-d<sub>7</sub>): &#x003b4; = 50.4 (CH<sub>2</sub>(mal)), 107.9 (C6), 152.6 (C3a), 152.8 (C2), 159.3 (C7), 179.8 (C5), 172.5 ppm (COO(mal)); <sup>15</sup>N NMR (50.6 MHz, dmf-d<sub>7</sub>): &#x003b4; = &#x02212;105.8 (N1), &#x02212;121.6 (N4), &#x02212;160.2 (N8), &#x02212;252.5 ppm (N3); <sup>195</sup>Pt NMR (107.4 MHz, dmf-d<sub>7</sub>): &#x02212;2609 ppm (s, PtO<sub>2</sub>NS). IR (KBr): 1344 (<bold>&#x003bd;<sub>sym(OCO</sub>&#x02014;<sub>)</sub></bold>), 1541 (<bold>&#x003bd;<sub>triazole ring</sub></bold>), 1617 (<bold>&#x003bd;<sub>pyrim ring</sub></bold>), 1662 cm<sup>&#x02212;1</sup> (<bold>&#x003bd;<sub>as(OCO</sub>&#x02014;<sub>)</sub></bold>).</p><p>Analysis found: C, 35.99; H, 4.79; N, 9.45%. Calculation for C<sub>18</sub>H<sub>28</sub>N<sub>4</sub>O<sub>5</sub>PtS: C, 35.59; H, 4.65; N, 9.22%.</p><p>(<bold>2</bold>) (Dimethylsulfoxide-<italic>&#x003ba;S</italic>)(7-isobutyl-5-methyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine-<italic>&#x003ba;N</italic>(3))(malonato- <italic>&#x003ba;<sup>2</sup>O,O&#x02032;</italic>)platinum(II) monoaqua hydrate</p><p>Yield: 0.0438 g (65.46%). <sup>1</sup>H NMR (499.8 MHz, dmf-d<sub>7</sub>): &#x003b4; = 3.52 (s, 6H, 2 &#x000d7; CH<sub>3</sub>(dmso)), 3.52 (s, 2H, CH<sub>2</sub>(mal)), 7.59 (s, H, H6), 9.15 ppm (s, H, H2); <sup>13</sup>C NMR (125.7 MHz, dmf-d<sub>7</sub>): &#x003b4; = 42.4 (CH<sub>2</sub>(mal)), 114.3 (C6), 151.9 (C7), 152.3 (C3a), 153.2 (C2), 169.5 (C5), 172.9 ppm (COO(mal)); <sup>15</sup>N NMR (50.6 MHz, dmf-d<sub>7</sub>): &#x003b4; = &#x02212;110.3 (N1), &#x02212;120.1 (N4), &#x02212;158.3 (N8), &#x02212;252.1 ppm (N3); <sup>195</sup>Pt NMR (107.4 MHz, dmf-d<sub>7</sub>): &#x02212;2598 ppm (s, PtO<sub>2</sub>NS). IR (KBr): 1351 (<bold>&#x003bd;<sub>sym(OCO</sub>&#x02014;<sub>)</sub></bold>), 1555 (<bold>&#x003bd;<sub>triazole ring</sub></bold>), 1636 (<bold>&#x003bd;<sub>pyrim ring</sub></bold>), 1662 cm<sup>&#x02212;1</sup> (<bold>&#x003bd;<sub>as(OCO</sub>&#x02014;<sub>)</sub></bold>). </p><p>Analysis found: C, 30.24; H, 4.52; N, 9.08%. Calculation for C<sub>15</sub>H<sub>24</sub>N<sub>4</sub>O<sub>6</sub>PtS (monohydrate): C, 30.87; H, 4.15; N, 9.60%.</p><p>(<bold>3</bold>) (Dimethylsulfoxide-<italic>&#x003ba;S</italic>)(5,7-di<italic>tert</italic>butyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine-<italic>&#x003ba;N</italic>(3))(cyclobutane-1,1- dicarboxylato-<italic>&#x003ba;<sup>2</sup>O,O&#x02032;</italic>))platinum(II) monoaqua hydrate</p><p>Yield, 0.0586 g (76.52%). <sup>1</sup>H NMR (499.8 MHz, dmf-d<sub>7</sub>): &#x003b4; = 1.79, 2.83, 3.03 (6H, CH<sub>2</sub>(CBDC)), 3.51 (s, 6H, 2 &#x000d7; CH<sub>3</sub>(dmso)), 7.55 (s, H, H6), 9.21 ppm (s, H, H2); <sup>13</sup>C NMR (125.7 MHz, dmf-d<sub>7</sub>): &#x003b4; = 107.0 (C6), 152.7 (C3a), 153.0 (C2), 159.0 (C7), 179.7 (C5) ppm. <sup>15</sup>N NMR (50.6 MHz, dmf-d<sub>7</sub>): &#x003b4; = &#x02212;106.0 (N1), &#x02212;122.0 (N4), &#x02212;161.0 (N8), &#x02212;253.0 ppm (N3); <sup>195</sup>Pt NMR (107.4 MHz, dmf-d<sub>7</sub>): &#x02212;2607 ppm (s, PtO<sub>2</sub>NS). IR (KBr): 1339 (<bold>&#x003bd;<sub>sym(OCO</sub>&#x02014;<sub>)</sub></bold>), 1542 (<bold>&#x003bd;<sub>triazole ring</sub></bold>), 1618 (<bold>&#x003bd;<sub>pyrim ring</sub></bold>), 1656 cm<sup>&#x02212;1</sup> (<bold>&#x003bd;<sub>as(OCO</sub>&#x02014;<sub>)</sub></bold>).</p><p>Analysis found: C, 38.30; H, 6.16; N, 8.00%. Calculation for C<sub>21</sub>H<sub>26</sub>N<sub>4</sub>O<sub>6</sub>PtS (monohydrate): C, 37.89; H, 5.15; N, 8.42%.</p><p>(<bold>4</bold>) (Dimethylsulfoxide-<italic>&#x003ba;S</italic>)(7-isobutyl-5-methyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine-<italic>&#x003ba;N</italic>(3))(cyclo- butane-1,1-dicarboxylato-<italic>&#x003ba;<sup>2</sup>O,O&#x02032;</italic>))platinum(II) monoaqua hydrate</p><p>Yield: 0.0498 g (69.54%). <sup>1</sup>H NMR (499.8 MHz, dmf-d<sub>7</sub>): &#x003b4; = 1.78, 2.80, 2.97 ( 6H, CH<sub>2</sub>(CBDC)), 3.51 (s, 6H, 2 &#x000d7; CH<sub>3</sub>(dmso)), 7.58 (s, H, H6), 9.16 ppm (s, H, H2); <sup>13</sup>C NMR (125.7 MHz, dmf-d<sub>7</sub>): &#x003b4; = 114.2 (C6), 151.9 (C7), 152.3 (C3a), 153.4 (C2), 169.4 (C5), 176.1, 176.5 ppm (COO(CBDC)). <sup>15</sup>N NMR (50.6 MHz, dmf-d<sub>7</sub>): &#x003b4; = &#x02212;110.3 (N1), &#x02212;119.8 (N4), &#x02212;158.3 (N8), &#x02212;251.7 ppm (N3); <sup>195</sup>Pt NMR (107.4 MHz, dmf-d<sub>7</sub>): &#x02212;2605 ppm (s, PtO<sub>2</sub>NS). IR (KBr): 1341 (<bold>&#x003bd;<sub>sym(OCO</sub>&#x02014;<sub>)</sub></bold>), 1555 (<bold>&#x003bd;<sub>triazole ring</sub></bold>), 1636 cm<sup>&#x02212;1</sup> (<bold>&#x003bd;<sub>pyrim ring</sub></bold>), 1669 (<bold>&#x003bd;<sub>as(OCO</sub>&#x02014;<sub>)</sub></bold>). </p><p>Analysis found: C, 34.90; H, 5.10; N, 8.68%. Calculation for C<sub>18</sub>H<sub>28</sub>N<sub>4</sub>O<sub>6</sub>PtS (monohydrate): C, 34.67; H, 4.53; N, 8.98%.</p><p>(<bold>5</bold>) (Dimethylsulfoxide-<italic>&#x003ba;S</italic>)(5,7-dimethyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine-<italic>&#x003ba;N</italic>(3))(malonato- <italic>&#x003ba;<sup>2</sup>O,O&#x02032;</italic>)platinum(II)</p><p>Details of the synthesis and spectroscopic characterization of the complex (<bold>5</bold>) were described previously [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot4-materials-13-05312"><title>2.4. Crystal Structure</title><p>Crystals of [Pt(mal)(DMSO)(dmtp)] (<bold>5</bold>) suitable for the diffraction experiments were obtained from the ethanol-water solution. The diffraction data were collected with the Sapphire CCD diffractometer (Oxford Diffraction, Abingdon, UK) using MoK&#x003b1; radiation &#x003bb; = 0.71073 &#x000c5; at 293(2) K by the &#x003c9;-2&#x003b8; method. The structure was solved by the Patterson method and refined with the full-matrix least-squares method on F<sup>2</sup> with the use of the SHELX2014 [<xref rid="B31-materials-13-05312" ref-type="bibr">31</xref>] program package (SHECLX2014/7, G. M. Sheldrick, Georg-August-Universit&#x000e4;t G&#x000f6;ttingen, G&#x000f6;ttingen, Germany). Analytical absorption correction was applied (<xref rid="materials-13-05312-t001" ref-type="table">Table 1</xref>) [<xref rid="B32-materials-13-05312" ref-type="bibr">32</xref>]. Positions of hydrogen atoms were found from the electron density maps, and hydrogen atoms were constrained in the refinement with the appropriate riding model as implemented in SHELX. The X-ray experimental data and structure refinement for the reported structure are summarized in <xref rid="materials-13-05312-t001" ref-type="table">Table 1</xref>. The structural data have been deposited with the Cambridge Crystallographic Data Centre, deposition number CCDC 2036218. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre [<xref rid="B33-materials-13-05312" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot5-materials-13-05312"><title>2.5. Partition Coefficient</title><p>The lipophilicity (log<italic>P</italic>) of the platinum(II) compounds was determined using the shake&#x02013;flask method [<xref rid="B34-materials-13-05312" ref-type="bibr">34</xref>]. At first, aqueous (0.9% <italic>w</italic>/<italic>v</italic>) sodium chloride and organic (<italic>n</italic>&#x02013;octanol) phases were saturated for 1 week. Complexes (<bold>2</bold>) and (<bold>3</bold>) were dissolved at a concentration of 0.30 mg mL<sup>&#x02212;1</sup> in 2.5 mL of saturated <italic>n</italic>-octanol, whereas cisplatin, carboplatin and complexes (<bold>1</bold>) and (<bold>4</bold>) were dissolved in the saturated aqueous phase. An equal volume of immiscible solvent was added, and the solutions were mixed mechanically in plastic tubes for 30 min. Samples were centrifuged (6000 rpm, 15 min). After separation, the phases were analyzed by UV&#x02013;Vis spectroscopy to determine the amount of the compound in each phase. The absorption values before and after shaking were compared, and based on the Lambert&#x02013;Beer law, the partition coefficient in both phases for each compound was calculated to determine the log<italic>P</italic> values. The procedures were repeated threefold.</p></sec><sec id="sec2dot6-materials-13-05312"><title>2.6. In Vitro Cytotoxicity</title><p>The in vitro antiproliferative activity against three human tumor cell lines, namely, non-small cell lung carcinoma (A549) (ATCC, Rockville, MD, USA), cisplatin-resistant human ductal breast epithelial tumor cells (T47D) (ATCC, Rockville, MD, USA) and colon cancer cells (LOVO) (ATCC, Rockville, MD, USA), and normal murine embryonic fibroblast cells (BALB/3T3) (ATCC, Rockville, MD, USA), was assessed.</p><p>Cells were plated in 96-well sterile plates (Sarstedt, Costar) at a density of 10<sup>4</sup> cells per well (in 100 &#x003bc;L of culture medium) and incubated for 24 h. The tested compound was added in final concentrations ranging from 0.1 to 100 &#x003bc;g mL<sup>&#x02212;1</sup>, and the incubation was continued for an additional 72 h. The results of in vitro cytotoxic activity are expressed as an IC<sub>50</sub> (the dose of compound (in &#x003bc;M) that inhibits proliferation rate of tumor cells by 50%) value compared to the untreated control cells. IC<sub>50</sub> values are expressed as the averages of three independently reproduced experiments. The details of this technique were described by Skehan [<xref rid="B35-materials-13-05312" ref-type="bibr">35</xref>]. The tests of the antiproliferative activity in vitro against both cell lines were performed with the SRB (sulforhodamine B) test using an automated microplate reader (Synergy H4 photometer, BioTek Instruments Inc., Winooski, VT, USA). Moreover, in vitro toxicity against normal murine fibroblast Balb3T3 cells was assessed. Finally, the in vitro toxicity results were compared to cisplatin, which was used as a reference at concentrations ranging from 0.01 to 10 &#x000b5;g/mL.</p></sec></sec><sec sec-type="results" id="sec3-materials-13-05312"><title>3. Results and Discussion</title><sec id="sec3dot1-materials-13-05312"><title>3.1. Multinuclear Magnetic Resonance Spectroscopy</title><p>From the application point of view, it is important to determine the environment of the central atom and the mode of the ligand binding method in platinum(II) complexes in solution. Therefore, the new dicarboxylato platinum(II) complexes were characterized in depth using multinuclear (<sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N, <sup>195</sup>Pt) NMR spectroscopy, and all coordination shifts were computed in comparison to the spectra of the corresponding free ligands (&#x00394;<sub>coord</sub> = &#x003b4;<sub>complex</sub> &#x02212; &#x003b4;<sub>ligand</sub>). The <sup>1</sup>H NMR spectra of (<bold>1</bold>&#x02013;<bold>4</bold>) exhibit three of the most distinctive signals for CH<sub>2</sub>(mal) or CH<sub>2</sub>(CBDC), and H(2) and H(6) from the heterocyclic ligands. In addition, one signal corresponding to the methyl groups of the DMSO ligand was found in the range from 3.51 to 3.52 ppm (<bold>1</bold>&#x02013;<bold>4</bold>). One signal at 3.56 ppm (<bold>1</bold>) and one at 3.52 ppm (<bold>2</bold>) from the mal group were observed, and signals at 1.79, 2.83 and 3.03 ppm (<bold>3</bold>) and 1.78, 2.80 and 2.97 ppm (<bold>4</bold>), all having an intensity of two, were assigned to the CBDC ring. These data were in agreement with the fact that the mal and CBDC groups act as bidentate chelating ligands through the two oxygen atoms of the carboxylato groups [<xref rid="B36-materials-13-05312" ref-type="bibr">36</xref>,<xref rid="B37-materials-13-05312" ref-type="bibr">37</xref>]. Furthermore, significant changes in the chemical shifts were observed for these hydrogen atoms from the heterocycle ligand in the aromatic region. The <sup>1</sup>H NMR spectra exhibit singlets of H(6) in the range of 7.55 to 7.59 ppm (&#x00394;<sub>coord</sub> = 0.21&#x02013;0.24 ppm). Notably, the largest coordination shifts were computed for H(2) from the triazole ring (maximum 0.74 ppm), which suggests the involvement of the N(1) or N(3) nitrogen atoms in the formation of Pt-N bonds. However, the <sup>1</sup>H NMR data were insufficient to determine which nitrogen atoms from the 5-membered ring participate in the complexation of triazolopyrimidines to platinum(II) ions. Therefore, <sup>15</sup>N&#x02013;<sup>1</sup>H NMR spectral analysis was necessary. The signals for all nitrogen atoms were detected in the range of &#x02212;105.8 to &#x02212;253.0 ppm (<xref rid="materials-13-05312-t002" ref-type="table">Table 2</xref>). Based on chemical shifts, it turned out that the coordination of the trizolopyrimidine to the Pt(II) caused shielding of all nitrogen atoms. However, the highest coordination shift (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub> = &#x003b4;<sup>15</sup>N<sub>complex</sub> &#x02212; &#x003b4;<sup>15</sup>N<sub>ligand</sub>) was revealed for resonance lines of N(3) signals. The calculated coordination shifts (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub>) ranged from &#x02212;62.7 to &#x02212;87.0 ppm (<xref rid="materials-13-05312-t002" ref-type="table">Table 2</xref>). These values were significantly different in comparison to those of the remaining nitrogen atoms. The strong shielding of the N(3) resonance signal clearly indicated the monodentate coordination of triazolopyrimidines to platinum(II) in solution, which was in good agreement with previous studies published for platinum(II) complexes with triazolopyrimidine derivatives [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>,<xref rid="B38-materials-13-05312" ref-type="bibr">38</xref>,<xref rid="B39-materials-13-05312" ref-type="bibr">39</xref>]. According to the literature data, the absolute values of the (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub>) for (<bold>1</bold>) and (<bold>2</bold>) complexes were lower than those found for symmetrical malonato platinum(II) complexes with two triazolopyrimidines: [Pt(mal)(dbtp)<sub>2</sub>] (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub> = &#x02212;99.6 ppm), [Pt(mal)(ibmtp)<sub>2</sub>] (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub> = &#x02212;108.5 ppm) [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>], or triazolopyrimidine and dimethyl sulfoxide [Pt(mal)(DMSO)(dmtp)] (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub> = &#x02212;98.3 ppm) (<xref rid="materials-13-05312-t002" ref-type="table">Table 2</xref>), [Pt(mal)(DMSO)(dptp)] (&#x00394;&#x003b4;<sup>15</sup>N<sub>coord</sub> = &#x02212;100.9 ppm) [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>].</p><p>To ultimately confirm the coordination mode of the triazolopyrimidine ligands to the central ion, <sup>13</sup>C NMR studies were investigated. A clear pattern for the coordination shifts for complexes (<bold>1</bold>&#x02013;<bold>4</bold>) was observed in the <sup>13</sup>C NMR spectra (<xref rid="materials-13-05312-t003" ref-type="table">Table 3</xref>). The signals from the C(3a) atom, which was adjacent directly to the N(3) coordination site, were deshielded by approximately &#x02212;4.1 to &#x02212;4.6 ppm compared with those of the free ligand, whereas the C(5), C(6) and C(7) resonances shifted to the opposite side of the spectrum (0.2&#x02013;3.3 ppm). This observation can be explained by the deshielding of the carbon atoms adjacent to the N(3) coordination site [<xref rid="B40-materials-13-05312" ref-type="bibr">40</xref>]. Furthermore, three additional signals from the malonato ligand were observed. One signal belonging to the carbon atom from CH<sub>2</sub> was found at 50.4 ppm (<bold>1</bold>) and 42.4 ppm (<bold>2</bold>), and two remaining signals from the two COO groups were found for both complexes (<bold>1)</bold> and (<bold>2)</bold> at 172.5 ppm and 172.9 ppm, respectively. Likewise, the <sup>13</sup>C NMR spectrum of complex (<bold>4</bold>) showed two signals at 176.1 and 176.5 ppm for the carbonyl carbon of coordinated carboxylate ligands. This suggests that the two carboxylato carbons are not magnetically equivalent in these complexes because one of carboxylato carbons is hindered by the proximity of the 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine ring. Different environments contribute to different chemical shifts. These values were also close to the values for carboxylato carbons reported for other symmetrical [<xref rid="B41-materials-13-05312" ref-type="bibr">41</xref>,<xref rid="B42-materials-13-05312" ref-type="bibr">42</xref>] and asymmetrical platinum(II) dicarboxylato complexes [<xref rid="B43-materials-13-05312" ref-type="bibr">43</xref>].</p><p>Nevertheless, the type of chromophore system present in the coordination sphere of (<bold>1</bold>&#x02013;<bold>4</bold>) can unequivocally be determined based on their <sup>195</sup>Pt resonances. <sup>195</sup>Pt NMR spectra of the compounds exhibited one signal between &#x02212;2598 and &#x02212;2609 ppm (<xref rid="materials-13-05312-t003" ref-type="table">Table 3</xref>). There were shifts in this signal towards higher fields in comparison with that of K<sub>2</sub>PtCl<sub>4</sub>, and that could be assigned to [PtNO<sub>2</sub>S] coordination for platinum(II) (<xref rid="materials-13-05312-t003" ref-type="table">Table 3</xref>). The observed presence of single resonance signals indicated monodentate structures of the novel coordination complexes. These results were in good agreement with those of previous studies [<xref rid="B23-materials-13-05312" ref-type="bibr">23</xref>,<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>]. Similar results of <sup>195</sup>Pt NMR data were obtained by Reedijk for chloride and cyclobutane-1,1-dicarboxylato platinum(II) complexes containing DMSO as a non-leaving group. <sup>195</sup>Pt singlets for <italic>cis</italic>-[PtCl<sub>2</sub>(A9pyp)(DMSO)] and [Pt(CBDC)(A9pyp)(DMSO)] were observed at &#x02212;3010 ppm [PtCl<sub>2</sub>NS] and &#x02212;2498 ppm [PtO<sub>2</sub>NS] [<xref rid="B23-materials-13-05312" ref-type="bibr">23</xref>]. Moreover, similar values of the <sup>195</sup>Pt chemical shift for complexes with two types of dicarboxylato ligands clearly confirmed that both the mal and CBDC leaving groups formed six-membered chelate rings upon complexation. The signals for previously synthesized [Pt(mal)(DMSO)(dmtp)], [Pt(CBDC)(DMSO)(dmtp)], [Pt(mal)(DMSO)(dptp)] and [Pt(CBDC)(DMSO)(dptp)] were observed in the same range of chemical shifts. Furthermore, previous studies from the &#x00141;akomska research group provide information that <sup>195</sup>Pt NMR resonances of the diiodido platinum(II) complex <italic>cis</italic>-[PtI<sub>2</sub>(dbtp)<sub>2</sub>] were observed at much higher fields, i.e., &#x02212;3261 ppm [PtI<sub>2</sub>N<sub>2</sub>], than were observed for its analogue [Pt(C<sub>4</sub>H<sub>4</sub>O<sub>5</sub>)(dbtp)<sub>2</sub>] containing dicarboxylato in the coordination sphere, &#x02212;1740 ppm [PtO<sub>2</sub>N<sub>2</sub>], and for its chloride analogue <italic>cis</italic>-[PtCl<sub>2</sub>(dbtp)<sub>2</sub>], &#x02212;2096 ppm [PtCl<sub>2</sub>N<sub>2</sub>] [<xref rid="B39-materials-13-05312" ref-type="bibr">39</xref>,<xref rid="B44-materials-13-05312" ref-type="bibr">44</xref>]. Additionally, signals from the <italic>trans</italic>-[PtI<sub>2</sub>(dbtp)(DMSO)] complex were observed at higher fields: &#x02212;4389 ppm [PtI<sub>2</sub>NS] [<xref rid="B40-materials-13-05312" ref-type="bibr">40</xref>]. Moreover, the chloride analogue <italic>trans</italic>-[PtCl<sub>2</sub>(dbtp)(DMSO)] exhibited a single peak at &#x02212;2955 ppm [PtCl<sub>2</sub>NS] [<xref rid="B45-materials-13-05312" ref-type="bibr">45</xref>]. Exactly the same trends were observed for the malonato platinum(II) complex [Pt(mal)(ibmtp)<sub>2</sub>]. <sup>195</sup>Pt singlet signals were found at &#x02212;1681 ppm [PtO<sub>2</sub>N<sub>2</sub>], while resonance signals of parent diiodido <italic>cis</italic>-[PtI<sub>2</sub>(ibmtp)<sub>2</sub>] were recorded at higher fields: &#x02212;3243 ppm [PtI<sub>2</sub>N<sub>2</sub>] [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>,<xref rid="B38-materials-13-05312" ref-type="bibr">38</xref>]. The above-mentioned data obtained by the &#x00141;akomska research group could be used to explain general trends in shielding during <sup>195</sup>Pt NMR (<xref ref-type="fig" rid="materials-13-05312-f002">Figure 2</xref>).</p></sec><sec id="sec3dot2-materials-13-05312"><title>3.2. Infrared Studies</title><p>The IR spectra of (<bold>1</bold>&#x02013;<bold>4</bold>) showed characteristic vibration bands: &#x003bd;<sub>as</sub>(OCO&#x02014;) 1662 cm<sup>&#x02212;1</sup> (<bold>1</bold>), 1657 cm<sup>&#x02212;1</sup> (<bold>2</bold>), 1656 cm<sup>&#x02212;1</sup> (<bold>3</bold>) and 1669 cm<sup>&#x02212;1</sup> (<bold>4</bold>); and the &#x003bd;s(OCO&#x02014;) 1344 cm<sup>&#x02212;1</sup> (<bold>1</bold>), 1351 cm<sup>&#x02212;1</sup> (<bold>2</bold>), 1339 cm<sup>&#x02212;1</sup> (<bold>3</bold>) and 1341 cm<sup>&#x02212;1</sup> (<bold>4</bold>) (<xref rid="materials-13-05312-t004" ref-type="table">Table 4</xref>). The mode of carboxylato coordination to a metal ion can be determined based on the &#x00394; values (&#x00394;=&#x003bd;<sub>as</sub>(OCO&#x02014;)-&#x003bd;<sub>s</sub>(OCO&#x02014;)). The calculated &#x00394; values of 318 cm<sup>&#x02212;1</sup> (<bold>1</bold>), 311 cm<sup>&#x02212;1</sup> (<bold>2</bold>), 317 cm<sup>&#x02212;1</sup> (<bold>3</bold>) and 328 cm<sup>&#x02212;1</sup> (<bold>4</bold>) compared to the &#x00394;&#x02019; value of disodium malonato (197 cm<sup>&#x02212;1</sup>) and of disodium cyclobutane-1,1-dicarboxylato (268 cm<sup>&#x02212;1</sup>) suggested a monodentate coordination mode for each carboxylic acid group. Furthermore, characteristic bands of the whole pyrimidine ring skeletal vibrations from novel dicarboxylato platinum(II) complexes appeared in the range of 1541&#x02013;1555 cm<sup>&#x02212;1</sup>, whereas those of the triazolopyrimidine ring appeared in the following range: 1617&#x02013;1636 cm<sup>&#x02212;1</sup> (<xref rid="materials-13-05312-t004" ref-type="table">Table 4</xref>). In the spectra of free ligands, the former band was found at 1530 cm<sup>&#x02212;1</sup> (dbtp) and 1544 cm<sup>&#x02212;1</sup> (ibmtp), and the latter band was found at 1615 cm<sup>&#x02212;1</sup> (dbtp) and 1621 cm<sup>&#x02212;1</sup> (ibmtp). Frequency values of absorption bands, which were assigned to relatively high frequencies in dicarboxylato complexes, clearly confirmed the coordination of dbtp and ibmtp to platinum(II) ions. Moreover, the two most characteristic bands, assigned as triazolopyrimidine ring skeletal vibrations and pyrimidine ring skeletal vibrations, were shifted by no more than 15 cm<sup>&#x02212;1</sup>. A similar effect was already observed for different complexes with 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine ligands, where N(3) coordination occurred [<xref rid="B44-materials-13-05312" ref-type="bibr">44</xref>,<xref rid="B45-materials-13-05312" ref-type="bibr">45</xref>,<xref rid="B46-materials-13-05312" ref-type="bibr">46</xref>]. Moreover, the strong absorption bands in the ranges of 1027&#x02013;1159 cm<sup>&#x02212;1</sup>
<bold>(1)</bold>, 1031&#x02013;1150 cm<sup>&#x02212;1</sup>
<bold>(2)</bold>, 1028&#x02013;1156 cm<sup>&#x02212;1</sup>
<bold>(3)</bold> and 1028&#x02013;1157 cm<sup>&#x02212;1</sup>
<bold>(4)</bold> indicated S-bonded DMSO, as expected for this typical soft coordination center [<xref rid="B47-materials-13-05312" ref-type="bibr">47</xref>,<xref rid="B48-materials-13-05312" ref-type="bibr">48</xref>,<xref rid="B49-materials-13-05312" ref-type="bibr">49</xref>,<xref rid="B50-materials-13-05312" ref-type="bibr">50</xref>].</p><p>Similar spectroscopic parameters were collected for PtO<sub>2</sub>NS complexes with 5,7-dimethyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine (dmtp) and 5,7-diphenyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine (dptp) [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>]. The ligand coordination mode suggested in the previous work and the geometry of the coordination sphere were correct, and we could confirm this by X-ray analysis of (<bold>5</bold>) [Pt(mal)(DMSO)(dmtp)]. This is the first example of mixed malonato platinum(II) complex with dimethyl sulfoxide and triazolopyrimidine ligands.</p></sec><sec id="sec3dot3-materials-13-05312"><title>3.3. X-ray Studies</title><p>Despite much effort, we were unable to obtain a single crystal of (<bold>1</bold>&#x02013;<bold>4</bold>) suitable for the diffraction experiments. However, we solved the crystal structure of an analogous platinum(II) complex with another 5,7-disubstituted-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine, 5,7-dimethyl-1,2,4-triazolo-[1,5-<italic>a</italic>]- pyrimidine (dmtp) [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>]. The asymmetric region of (<bold>5</bold>) [Pt(mal)(DMSO)(dmtp)] consists of a single [Pt(mal)(DMSO)(dmtp)] molecule (<xref ref-type="fig" rid="materials-13-05312-f003">Figure 3</xref>).</p><p>The coordination sphere PtNO<sub>2</sub>S had square-planar geometry. Despite the charged carboxylic groups bound to Pt, the Pt&#x02013;N and Pt&#x02013;O bond lengths were similar (<xref ref-type="fig" rid="materials-13-05312-f003">Figure 3</xref>) and significantly shorter than the Pt1&#x02013;S1 bond of 2.1979(15) &#x000c5;. Such geometry was found in similar complexes reported previously [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>,<xref rid="B51-materials-13-05312" ref-type="bibr">51</xref>]. The angular deformations within the coordination sphere were small, with cis angles varying from 87.10(19) to 93.37(15)&#x000b0;, while those between bonds to the ligands positioned trans were O3&#x02013;Pt1&#x02013;N3 175.88(19)&#x000b0; and O1&#x02013;Pt1&#x02013;S1 178.81(13)&#x000b0;. The O3&#x02013;Pt1&#x02013;O1 angle between the coordination bonds formed by malonate was 90.40(17)&#x000b0;. For the NO<sub>2</sub>S coordination sphere, the rms deviation of atoms from the best plane was 0.039 &#x000c5;, and the Pt1 deviation from that plane was &#x02212;0.018 &#x000c5;.</p><p>The valence geometry of dmtp was typical for such systems. The tilt of the dmtp ring system relative to the coordination plane might be described with a C3A-N3-Pt1-O1 torsion angle of &#x02212;127.0(5)&#x000b0;. The dihedral angle between the best plane of the dmtp ring system and the NO<sub>2</sub>S coordination plane was 53.5(1)&#x000b0; with rotation around the Pt1&#x02013;N3 bond in a direction minimizing the dmtp interactions with O26 of DMSO. In this orientation, interactions were found between the C25 methyl group of DMSO and the C51 methyl group of dmtp.</p><p>In the reported complex, the malonate ion was a bidentate ligand. The presence of three single bonds allowed for the relaxation of possible strain by rotation of both carboxylic groups relative to the C21-C22-C23 fragment, with the dihedral angles between this fragment and O1-C21-O2-C22 and O3-C23-O4-C22 and the best planes being 33.6(4)&#x000b0; and 50.3(7)&#x000b0;, while that between the two carboxylic groups was 83.9(4)&#x000b0;. The six-membered chelate ring formed by malonate (<xref ref-type="fig" rid="materials-13-05312-f003">Figure 3</xref>) had a boat conformation.</p><p>The valence geometry of DMSO was typical. The orientation of this ligand relative to the coordination plane was reflected in the N3-Pt1-S1-O26 and N3-Pt1-S1-C25 torsion angles of 24.6(3)&#x000b0; and &#x02212;102.1(3)&#x000b0;, respectively.</p></sec><sec id="sec3dot4-materials-13-05312"><title>3.4. Lipophilicity</title><p>The lipophilicity of the investigated compounds increased in the order of (<bold>1</bold>) &#x0003c; (<bold>3</bold>) &#x0003c; (<bold>4</bold>) &#x0003c; (<bold>2</bold>) (<xref ref-type="fig" rid="materials-13-05312-f004">Figure 4</xref>). These values can be compared with data available in the literature for currently used inorganic platinum(II) drugs, namely, cisplatin (&#x02212;2.53), carboplatin (&#x02212;2.30) and oxaliplatin (&#x02212;1.76) [<xref rid="B52-materials-13-05312" ref-type="bibr">52</xref>]. It is important to note that that all studied platinum(II) complexes exhibited increased lipophilicity in comparison to those of all three international anticancer drugs.</p><p>Additionally, the study indicated that the log<italic>P</italic> for complexes (<bold>1</bold>&#x02013;<bold>4</bold>) correlated with the type of dicarboxylate ligand (leaving ligands). The obtained results confirmed that the malonato platinum(II) complexes [Pt(mal)(dbtp)(DMSO)] (&#x02212;1.58) and [Pt(mal)(DMSO)(ibmtp)] (&#x02212;0.65) were more lipophilic than their cyclobutane-1,1-dicarboxylate analogues [Pt(CBDC)(dbtp)(DMSO)] (&#x02212;1.69) and [Pt(CBDC)(DMSO)(ibmtp)] (&#x02212;1.23).</p><p>According to the literature, cellular uptake is a commonly known factor influencing drug efficacy. Additionally, cellular uptake of platinum(II) complexes by passive diffusion correlates with their lipophilicities [<xref rid="B53-materials-13-05312" ref-type="bibr">53</xref>]. Lipophilicity has been widely investigated in quantitative structure&#x02013;activity relationships (QSARs) for bioavailability, transmembrane transport or cellular drug accumulation [<xref rid="B54-materials-13-05312" ref-type="bibr">54</xref>]. Currently, the lipophilicity of drugs is related to their ability to cross cell membranes by passive diffusion. Moreover, this parameter can be correlated with the relative solubility of the molecule in lipid bilayers and the aqueous environment in cells. Increasing the lipophilic character of platinum(II) complexes facilitates drug accumulation via the lipid bilayer of the cell membrane. However, such high lipophilicity simultaneously decreases aqueous solubility, which finally impedes drug application [<xref rid="B55-materials-13-05312" ref-type="bibr">55</xref>].</p><p>Generally, platinum(II) complexes are hydrophilic, with negative log<italic>P</italic>o/w values [<xref rid="B56-materials-13-05312" ref-type="bibr">56</xref>]. However, the addition of large nonpolar ligands such as 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine derivatives can increase lipophilicity. Following the previous work of the &#x00141;akomska research group, the [Pt(mal)(ibmtp)<sub>2</sub>] (0.80) and [Pt(mal)(dbtp)<sub>2</sub>] (2.07) complexes possessed positive log<italic>P</italic> values [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>], which indicated their relatively high lipophilicity. The neutral ligands imparted lipophilic character to the dicarboxylato platinum(II) complexes; however, these ligands also reduced their water solubility. On the basis of these findings, we decided to modify the structure of dicarboxylato platinum(II) complexes by introducing the DMSO molecule as a S-donor non-leaving group.</p></sec><sec id="sec3dot5-materials-13-05312"><title>3.5. In Vitro Antiproliferative Activity</title><p>The in vitro cytotoxicity of the studied platinum(II) complexes (<bold>1</bold>&#x02013;<bold>4</bold>) against A549, LoVo and T47D cells is summarized in <xref rid="materials-13-05312-t005" ref-type="table">Table 5</xref>. The obtained results (<xref rid="materials-13-05312-t005" ref-type="table">Table 5</xref>) clearly indicated that the platinum(II) complexes with the dbtp molecule as the non-leaving group possessed higher in vitro cytotoxicity than that of platinum(II) analogues with the ibmtp molecule. Additionally, it could be detected that both dicarboxylato leaving groups possessed comparable influences on the cytotoxicity of the platinum(II) complexes. This can be caused by the fact that both mal and CBDC ligand chelation produced six-membered rings with platinum(II) ions, which provide the same stability and activity. Among all dicarboxylato platinum(II) complexes, (<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)] exhibited significant in vitro cytotoxic activity against A549 and T47D cancer cells. These results confirmed that complexes with bulky triazolopyrimidine ligands exhibit relatively high activity against cancer cell lines, which was in good agreement with previous studies [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>,<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>]. Additionally, based on these results, there was a clear correlation between lipophilicity and in vitro activity. The most lipophilic complexes, namely, (<bold>1</bold>) [Pt(mal)(dbtp)(DMSO)] and (<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)], showed better antiproliferative activity than that of the more hydrophilic complexes. Due to the highly toxic activity of platinum compounds against normal cells, there was a requirement to investigate their antiproliferative activity against normal cells. Thus, the in vitro toxicity towards normal mouse embryonic fibroblast cells was estimated. The (<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)] complex revealed lower toxicity to BALB/3T3 cells than cisplatin.</p><p>Our previous [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>] and current in vitro results agree with two main mechanistic assumptions concerning the design and synthesis of novel platinum(II) drugs. First, replacement of the leaving group influenced the activity by pharmacological properties. Second, adding an appropriate carrier group to a transition metal can grant more favorable DNA binding properties [<xref rid="B57-materials-13-05312" ref-type="bibr">57</xref>]. Such a tendency can be observed among the activities of our dicarboxylato platinum(II) complexes (<xref ref-type="fig" rid="materials-13-05312-f005">Figure 5</xref>). On the one hand, substitution of the mal ligand by the CBDC group increased the activity. On the other hand, substitution of one of the 5,7-di<italic>tert</italic>butyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine carrier ligands by the DMSO molecule slightly decreased the in vitro cytotoxicity. This can be explained by the relatively low capacity of interaction between bases in DNA and DMSO. Bulky ligands such as 5,7-di<italic>tert</italic>butyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine possess a higher capacity to increase the intercalation with DNA than the smaller DMSO molecules. Such a tendency is revealed in results against non-small cell lung carcinoma (A549) and breast cancer (T-47D) cells.</p><p>The results once again emphasize [<xref rid="B22-materials-13-05312" ref-type="bibr">22</xref>,<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>] the significant influences of type of triazolopyrimidine ligand (especially the types of substituent at positions 5 and 7) and the composition of the coordination sphere on the formation of cytotoxic platinum(II) complexes. These things are very useful in the design of new antitumor drugs, but in the future it will be necessary to enrich understanding with advanced research aimed at understanding their mechanisms of action.</p><p>Additionally, we analyzed the in vitro antiproliferative activity of the most promising compound (<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)], cisplatin and our previously described platinum(II) complex with another 5,7-disubstituted-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine (dptp), [Pt(mal)(DMSO)(dptp)], where dptp is 5,7-diphenyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>]. Within this group of compounds, [Pt(mal)(DMSO)(dptp)] exhibited the most selective cytotoxicity in vitro (IC<sub>50</sub> = 10.1 &#x000b1; 10.7 &#x000b5;M). This complex showed similar anticancer activity to that of cisplatin (IC<sub>50</sub> = 9.00 &#x000b1; 1.1 &#x000b5;M) and (<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)] (IC<sub>50</sub> = 5.00 &#x000b1; 0.9 &#x000b5;M) towards the A549 cell line. Moreover, the most significant advantage of this complex was that it exhibited low toxicity (IC<sub>50</sub> = 37.1 &#x000b1; 7.0 &#x000b5;M) towards the BALB/3T3 normal cell line in comparison with that of cisplatin (IC<sub>50</sub> = 3.20 &#x000b1; 1.5 &#x000b5;M) and complex (<bold>3</bold>) (IC<sub>50</sub> = 10.19 &#x000b1; 13.2 &#x000b5;M). For that reason, we can suggest that the use of 5,7-diphenyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine as an N-donor ligand as an appropriate way to design selective anticancer platinum(II) compounds.</p></sec></sec><sec sec-type="conclusions" id="sec4-materials-13-05312"><title>4. Conclusions</title><p>Motivated by the success of cisplatin, carboplatin and oxaliplatin in cancer treatments, we made efforts to investigate new dicarboxylato platinum(II) complexes. Here, we report a series of novel, mixed dicarboxylato platinum(II) complexes, namely, the two mononuclear malonato platinum(II) complexes - [Pt(mal)(DMSO)(dbtp)] (<bold>1</bold>) and [Pt(mal)(DMSO)(ibmtp)] (<bold>2</bold>); and the two mononuclear cyclobutane-1,1-dicarboxylato complexes - [Pt(CBDC)(DMSO)(dbtp)] (<bold>3</bold>) and [Pt(CBDC)(DMSO)(ibmtp)] (<bold>4</bold>), which were successfully synthesized and fully characterized using <sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N and <sup>195</sup>Pt NMR and IR spectroscopy. Considering the IR spectra of the complexes along with the results obtained from experimental and computational studies, it was concluded that each carboxylic acid group exhibited a monodentate coordination mode. Significant <sup>15</sup>N NMR shielding (62&#x02013;87 ppm) was observed for the N(3) atom. These data indicated that coordination of the investigated 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidines to platinum(II) ions occurs via N(3). Additionally, the results obtained from NMR studies confirmed the existence of all novel complexes in solution. This evidence is highly essential with respect to the biological applications of these platinum(II) complexes (<bold>1</bold>&#x02013;<bold>4</bold>), who were more lipophilic than the most common anticancer drugs, such as cisplatin and the dicarboxylato analogues carboplatin and oxaliplatin. Finally, among all dicarboxylato platinum(II) complexes, [Pt(CBDC)(dbtp)(DMSO)] (<bold>3</bold>) exhibited significant in vitro cytotoxic activity against A549 and T47D cancer cell lines.</p><p>In summary, the [Pt(CBDC)(DMSO)(dbtp)] (<bold>3</bold>) complex was shown to be a promising candidate as an anticancer drug due to the following factors:<list list-type="simple"><list-item><label><bold>(i)</bold>&#x000a0;</label><p>Relevant cytotoxic activity against A-549 (non-small cell lung carcinoma) and T47D (breast cancer) cells;</p></list-item><list-item><label><bold>(ii)</bold>&#x000a0;</label><p>Better selectivity against A549 and T47D than cisplatin;</p></list-item><list-item><label><bold>(iii)</bold>&#x000a0;</label><p>Lower toxicity against normal BALB/3T3 cells than that of cisplatin.</p></list-item></list></p></sec></body><back><ack><title>Acknowledgments</title><p>I.&#x00141;. and M.J. would like to thank COST Action CA18202, NECTAR&#x02014;Network for Equilibria and Chemical Thermodynamics Advanced Research, supported by COST (European Cooperation in Science and Technology). I.&#x00141;., M.J. and A.W. are members of the Centre of Excellence &#x0201c;Towards Personalized Medicine&#x0201d; operating under the Excellence Initiative&#x02014;Research University.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, I.&#x00141;.; methodology, D.&#x0015a;. and J.S.; formal analysis, D.&#x0015a;. and J.S.; investigation, D.&#x0015a;., J.S., M.J. and A.W.; writing&#x02014;original draft preparation, I.&#x00141;., D.&#x0015a;., A.W. and M.J.; writing&#x02014;review and editing, I.&#x00141;. and M.J.; visualization, D.&#x0015a;. and M.J.; and supervision, I.&#x00141;. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>Publication costs were supported by the Nicolaus Copernicus University in Toru&#x00144; (Excellence Initiative&#x02014;Research University).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-materials-13-05312"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moucheron</surname><given-names>C.</given-names></name></person-group><article-title>From cisplatin to photoreactive Ru complexes: Targeting DNA for biomedical applications</article-title><source>New J. Chem.</source><year>2009</year><volume>33</volume><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1039/B817016A</pub-id></element-citation></ref><ref id="B2-materials-13-05312"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharti</surname><given-names>S.K.</given-names></name><name><surname>Singh</surname><given-names>S.K.</given-names></name></person-group><article-title>Recent development in the field of anticancer metallopharmaceuticals</article-title><source>Int. J. PharmTech Res.</source><year>2009</year><volume>1</volume><fpage>1406</fpage><lpage>1420</lpage></element-citation></ref><ref id="B3-materials-13-05312"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pucci</surname><given-names>D.</given-names></name><name><surname>Bellusci</surname><given-names>A.</given-names></name><name><surname>Bernardini</surname><given-names>S.</given-names></name><name><surname>Bloise</surname><given-names>R.</given-names></name><name><surname>Crispini</surname><given-names>A.</given-names></name><name><surname>Federici</surname><given-names>G.</given-names></name><name><surname>Liguori</surname><given-names>P.</given-names></name><name><surname>Lucas</surname><given-names>M.F.</given-names></name><name><surname>Russo</surname><given-names>N.</given-names></name><name><surname>Valentini</surname><given-names>A.</given-names></name></person-group><article-title>Bioactive fragments synergically involved in the design of new generation Pt(II) and Pd(II)-based anticancer compounds</article-title><source>Dalton Trans.</source><year>2008</year><volume>43</volume><fpage>5897</fpage><lpage>5904</lpage><pub-id pub-id-type="doi">10.1039/b808093c</pub-id><?supplied-pmid 19082045?><pub-id pub-id-type="pmid">19082045</pub-id></element-citation></ref><ref id="B4-materials-13-05312"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>S.D.</given-names></name><name><surname>Trotter</surname><given-names>K.D.</given-names></name><name><surname>Sutcliffe</surname><given-names>O.B.</given-names></name><name><surname>Plumb</surname><given-names>J.A.</given-names></name><name><surname>Waddell</surname><given-names>B.</given-names></name><name><surname>Briggsa</surname><given-names>N.E.B.</given-names></name><name><surname>Wheate</surname><given-names>N.J.</given-names></name></person-group><article-title>Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity</article-title><source>Dalton Trans.</source><year>2012</year><volume>41</volume><fpage>11330</fpage><lpage>11339</lpage><pub-id pub-id-type="doi">10.1039/c2dt31313h</pub-id><pub-id pub-id-type="pmid">22886151</pub-id></element-citation></ref><ref id="B5-materials-13-05312"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheate</surname><given-names>N.J.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Craig</surname><given-names>G.E.</given-names></name><name><surname>Oun</surname><given-names>R.</given-names></name></person-group><article-title>The status of platinum anticancer drugs in the clinic and in clinical trials</article-title><source>Dalton Trans.</source><year>2010</year><volume>39</volume><fpage>8113</fpage><lpage>8127</lpage><pub-id pub-id-type="doi">10.1039/c0dt00292e</pub-id><pub-id pub-id-type="pmid">20593091</pub-id></element-citation></ref><ref id="B6-materials-13-05312"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Rijt</surname><given-names>S.H.</given-names></name><name><surname>Sadler</surname><given-names>P.J.</given-names></name></person-group><article-title>Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs</article-title><source>Drug Discov. Today</source><year>2009</year><volume>14</volume><fpage>1089</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2009.09.003</pub-id><pub-id pub-id-type="pmid">19782150</pub-id></element-citation></ref><ref id="B7-materials-13-05312"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberoi</surname><given-names>H.S.</given-names></name><name><surname>Nukolova</surname><given-names>N.V.</given-names></name><name><surname>Kabanov</surname><given-names>A.V.</given-names></name><name><surname>Bronich</surname><given-names>T.K.</given-names></name></person-group><article-title>Nanocarriers for delivery of platinum anticancer drugs</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>1667</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.09.014</pub-id><pub-id pub-id-type="pmid">24113520</pub-id></element-citation></ref><ref id="B8-materials-13-05312"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>M.D.</given-names></name><name><surname>Hambley</surname><given-names>T.W.</given-names></name></person-group><article-title>Platinum(IV) antitumor compounds: Their bioinorganic chemistry</article-title><source>Coord. Chem. Rev.</source><year>2002</year><volume>232</volume><fpage>49</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/S0010-8545(02)00026-7</pub-id></element-citation></ref><ref id="B9-materials-13-05312"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>N.</given-names></name><name><surname>Lippard</surname><given-names>S.J.</given-names></name></person-group><article-title>Redox activation of metal-based prodrugs as a strategy for drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2012</year><volume>64</volume><fpage>993</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.01.007</pub-id><pub-id pub-id-type="pmid">22289471</pub-id></element-citation></ref><ref id="B10-materials-13-05312"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>TJohnstone</surname><given-names>C.</given-names></name><name><surname>Kulak</surname><given-names>N.</given-names></name><name><surname>Pridgen</surname><given-names>E.M.</given-names></name><name><surname>Farokhazd</surname><given-names>O.C.</given-names></name><name><surname>Langer</surname><given-names>R.</given-names></name><name><surname>Lippard</surname><given-names>S.J.</given-names></name></person-group><article-title>Nanoparticles encapsulation of mitaplatin and the effect thereof on in vivo properties</article-title><source>ACS Nano</source><year>2013</year><volume>7</volume><fpage>5675</fpage><lpage>5683</lpage><pub-id pub-id-type="pmid">23697579</pub-id></element-citation></ref><ref id="B11-materials-13-05312"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>R.G.</given-names></name><name><surname>Marmion</surname><given-names>C.J.</given-names></name></person-group><article-title>Toward multi-targeted platinum and ruthenium drugs- a new paradigm in cancer drug treatment regimens?</article-title><source>Chem. Rev.</source><year>2019</year><volume>119</volume><fpage>1058</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00271</pub-id><?supplied-pmid 30640441?><pub-id pub-id-type="pmid">30640441</pub-id></element-citation></ref><ref id="B12-materials-13-05312"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Towards the rational design of platinum(<sc>II</sc>) and gold(<sc>III</sc>) complexes as antitumour agents</article-title><source>Dalton Trans.</source><year>2008</year><volume>12</volume><fpage>1521</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1039/B715903J</pub-id><?supplied-pmid 18335133?><pub-id pub-id-type="pmid">18335133</pub-id></element-citation></ref><ref id="B13-materials-13-05312"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schluga</surname><given-names>P.</given-names></name><name><surname>Hartinger</surname><given-names>C.G.</given-names></name><name><surname>Galanski</surname><given-names>M.</given-names></name><name><surname>Meelich</surname><given-names>K.</given-names></name><name><surname>Timerbaev</surname><given-names>A.R.</given-names></name><name><surname>Keppler</surname><given-names>B.K.</given-names></name></person-group><article-title>Tumour-inhibiting platinum(II) complexes with aminoalcohol ligands: Biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry</article-title><source>Analyst</source><year>2005</year><volume>130</volume><fpage>1383</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1039/b506490b</pub-id><?supplied-pmid 16172663?><pub-id pub-id-type="pmid">16172663</pub-id></element-citation></ref><ref id="B14-materials-13-05312"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Goddard</surname><given-names>R.</given-names></name><name><surname>P&#x000f6;rschke</surname><given-names>K.R.</given-names></name><name><surname>Hamacher</surname><given-names>A.</given-names></name><name><surname>Kassack</surname><given-names>M.U.</given-names></name></person-group><article-title>Bispidine Analogues of Cisplatin, Carboplatin, and Oxaliplatin. Synthesis, Structures, and Cytotoxicity</article-title><source>Inorg. Chem.</source><year>2014</year><volume>53</volume><fpage>3371</fpage><lpage>3384</lpage><pub-id pub-id-type="doi">10.1021/ic402737f</pub-id><pub-id pub-id-type="pmid">24665859</pub-id></element-citation></ref><ref id="B15-materials-13-05312"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Gou</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name></person-group><article-title>Anticancer potency of platinum(II) complexes containing both chloride anion and chelated carboxylate as leaving groups</article-title><source>Inorg. Chem.</source><year>2013</year><volume>52</volume><fpage>8163</fpage><lpage>8170</lpage><pub-id pub-id-type="doi">10.1021/ic400907t</pub-id><pub-id pub-id-type="pmid">23808547</pub-id></element-citation></ref><ref id="B16-materials-13-05312"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasetto</surname><given-names>L.M.</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>M.R.</given-names></name><name><surname>Brandes</surname><given-names>A.A.</given-names></name><name><surname>Rossi</surname><given-names>E.</given-names></name><name><surname>Monfardini</surname><given-names>S.</given-names></name></person-group><article-title>The development of platinum compounds and their possible combination</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2006</year><volume>60</volume><fpage>59</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2006.02.003</pub-id><pub-id pub-id-type="pmid">16806960</pub-id></element-citation></ref><ref id="B17-materials-13-05312"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnecke</surname><given-names>A.</given-names></name><name><surname>Fichtner</surname><given-names>I.</given-names></name><name><surname>Garmann</surname><given-names>D.</given-names></name><name><surname>Jaehde</surname><given-names>U.</given-names></name><name><surname>Kratz</surname><given-names>F.</given-names></name></person-group><article-title>Synthesis and Biological Activity of Water-Soluble Maleimide Derivatives of the Anticancer Drug Carboplatin Designed as Albumin-Binding Prodrugs</article-title><source>Bioconjugate Chem.</source><year>2004</year><volume>15</volume><fpage>1349</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1021/bc049829j</pub-id></element-citation></ref><ref id="B18-materials-13-05312"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Pasqua</surname><given-names>A.J.</given-names></name><name><surname>Centerwall</surname><given-names>C.R.</given-names></name><name><surname>Kerwood</surname><given-names>D.J.</given-names></name><name><surname>Dabrowiak</surname><given-names>J.C.</given-names></name></person-group><article-title>Formation of Carbonato and Hydroxo Complexes in the Reaction of Platinum Anticancer Drugs with Carbonate</article-title><source>Inorg. Chem.</source><year>2009</year><volume>48</volume><fpage>1192</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1021/ic801579h</pub-id><pub-id pub-id-type="pmid">19113934</pub-id></element-citation></ref><ref id="B19-materials-13-05312"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuduk-Jaworska</surname><given-names>J.</given-names></name><name><surname>Waszkiewicz</surname><given-names>K.</given-names></name></person-group><article-title>Malatoplatinum(II) complexes&#x02014;Carboplatin analogs</article-title><source>Transit. Met. Chem.</source><year>2000</year><volume>25</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1023/A:1007042111791</pub-id></element-citation></ref><ref id="B20-materials-13-05312"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;tarha</surname><given-names>P.</given-names></name><name><surname>Tr&#x000e1;vn&#x000ed;&#x0010d;ek</surname><given-names>Z.</given-names></name><name><surname>Popa</surname><given-names>A.</given-names></name><name><surname>Popa</surname><given-names>I.</given-names></name><name><surname>Muchov&#x000e1;</surname><given-names>T.</given-names></name><name><surname>Brabec</surname><given-names>V.</given-names></name></person-group><article-title>How to modify 7-azaindole to form cytotoxic Pt(II) complexes: Highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole</article-title><source>J. Inorg. Biochem.</source><year>2012</year><volume>115</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2012.05.006</pub-id><pub-id pub-id-type="pmid">22922312</pub-id></element-citation></ref><ref id="B21-materials-13-05312"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x00159;ikavov&#x000e1;</surname><given-names>R.</given-names></name><name><surname>Hanouskov&#x000e1;</surname><given-names>L.</given-names></name><name><surname>Dvo&#x00159;&#x000e1;k</surname><given-names>Z.</given-names></name><name><surname>Tr&#x000e1;vn&#x000ed;&#x0010d;ek</surname><given-names>Z.</given-names></name></person-group><article-title>Dichlorido-platinum(II) complexes with kinetin derivatives as promising cytotoxic agents avoiding resistance of cancer cells: Contrasting results between cisplatin and oxaliplatin analogues</article-title><source>Polyhedron</source><year>2015</year><volume>90</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.poly.2015.01.033</pub-id></element-citation></ref><ref id="B22-materials-13-05312"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Hoffmann</surname><given-names>K.</given-names></name><name><surname>Wojtczak</surname><given-names>A.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name><name><surname>Maj</surname><given-names>E.</given-names></name><name><surname>Wietrzyk</surname><given-names>J.</given-names></name></person-group><article-title>Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-<italic>a</italic>] pyrimidine derivatives: Structural characterization and mechanism of the suppression of tumor cell growth</article-title><source>J. Inorg. Biochem.</source><year>2014</year><volume>141</volume><fpage>188</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2014.08.005</pub-id><?supplied-pmid 25277461?><pub-id pub-id-type="pmid">25277461</pub-id></element-citation></ref><ref id="B23-materials-13-05312"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marqu&#x000e9;s-Gallego</surname><given-names>P.</given-names></name><name><surname>Contaldi</surname><given-names>S.</given-names></name><name><surname>den Dulk</surname><given-names>H.</given-names></name><name><surname>Monari</surname><given-names>M.</given-names></name><name><surname>Brouwer</surname><given-names>J.</given-names></name><name><surname>Jaehde</surname><given-names>U.</given-names></name><name><surname>Kalayda</surname><given-names>G.V.</given-names></name><name><surname>Reedijk</surname><given-names>J.</given-names></name></person-group><article-title>Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand</article-title><source>J. Inorg. Biochem.</source><year>2009</year><volume>103</volume><fpage>1602</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.08.009</pub-id><?supplied-pmid 19783310?><pub-id pub-id-type="pmid">19783310</pub-id></element-citation></ref><ref id="B24-materials-13-05312"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>L.</given-names></name><name><surname>Popa</surname><given-names>I.</given-names></name><name><surname>Starha</surname><given-names>P.</given-names></name><name><surname>Travnicek</surname><given-names>Z.</given-names></name></person-group><article-title><italic>In Vitro</italic> Cytotoxic-Active Platinum(II) Complexes Derived from Carboplatin and Involving Purine Derivatives</article-title><source>Eur. J. Inorg. Chem.</source><year>2010</year><volume>22</volume><fpage>3441</fpage><lpage>3448</lpage><pub-id pub-id-type="doi">10.1002/ejic.201000322</pub-id></element-citation></ref><ref id="B25-materials-13-05312"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubowski</surname><given-names>M.</given-names></name><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name><name><surname>Wi&#x0015b;niewska</surname><given-names>J.</given-names></name></person-group><article-title>Dicarboxylato platinum(<sc>II)</sc> complexes containing dimethyl sulfoxide and triazolopyrimidine as potential anticancer agents: Synthesis, structural and biological studies in solution</article-title><source>New J. Chem.</source><year>2018</year><volume>42</volume><fpage>8113</fpage><lpage>8122</lpage><pub-id pub-id-type="doi">10.1039/C8NJ01199K</pub-id></element-citation></ref><ref id="B26-materials-13-05312"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furrer</surname><given-names>J.</given-names></name><name><surname>Robust</surname><given-names>A.</given-names></name></person-group><article-title>A robust, sensitive, and versatile HMBC experiment for rapid structure elucidation by NMR: IMPACT-HMBC</article-title><source>Chem. Commun.</source><year>2010</year><volume>46</volume><fpage>3396</fpage><lpage>3398</lpage><pub-id pub-id-type="doi">10.1039/c000964d</pub-id></element-citation></ref><ref id="B27-materials-13-05312"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupce</surname><given-names>E.</given-names></name><name><surname>Freeman</surname><given-names>R.</given-names></name></person-group><article-title>Fast multidimensional NMR by polarization sharing</article-title><source>Magn. Reson. Chem.</source><year>2007</year><volume>45</volume><fpage>2</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1002/mrc.1931</pub-id><pub-id pub-id-type="pmid">17125135</pub-id></element-citation></ref><ref id="B28-materials-13-05312"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grodzicki</surname><given-names>A.</given-names></name><name><surname>Sz&#x00142;yk</surname><given-names>E.</given-names></name><name><surname>Pazderski</surname><given-names>L.</given-names></name><name><surname>Goli&#x00144;ski</surname><given-names>A.</given-names></name></person-group><article-title>NMR Properties of 5,7-Disubstituted Derivatives of 1,2,4-Triazolo[ 1,5a] pyrimidine</article-title><source>Magn. Reson. Chem.</source><year>1996</year><volume>34</volume><fpage>725</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-458X(199609)34:9&#x0003c;725::AID-OMR939&#x0003e;3.0.CO;2-Z</pub-id></element-citation></ref><ref id="B29-materials-13-05312"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rochon</surname><given-names>F.D.</given-names></name><name><surname>Massarweh</surname><given-names>G.</given-names></name></person-group><article-title>Synthesis, multinuclear magnetic resonance and crystal structures of Pt(II) complexes containing amines and bidentate carboxylate ligands</article-title><source>Inorg. Chim. Acta</source><year>2006</year><volume>359</volume><fpage>4095</fpage><lpage>4104</lpage><pub-id pub-id-type="doi">10.1016/j.ica.2006.04.014</pub-id></element-citation></ref><ref id="B30-materials-13-05312"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>J.H.</given-names></name><name><surname>Williamson</surname><given-names>A.S.</given-names></name><name><surname>Schramm</surname><given-names>R.S.</given-names></name><name><surname>Wayland</surname><given-names>B.B.</given-names></name></person-group><article-title>Palladium(II) and platinum(II) alkyl sulfoxide complexes. Examples of sulfur-bonded, mixed sulfur- and oxygen-bonded, and totally oxygen-bonded complexes</article-title><source>Inorg. Chem.</source><year>1972</year><volume>11</volume><fpage>1280</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1021/ic50112a025</pub-id></element-citation></ref><ref id="B31-materials-13-05312"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheldrick</surname><given-names>G.M.</given-names></name></person-group><article-title>A Short History of SHELX</article-title><source>Acta Crystallogr. A</source><year>2008</year><volume>64</volume><fpage>112</fpage><pub-id pub-id-type="doi">10.1107/S0108767307043930</pub-id><?supplied-pmid 18156677?><pub-id pub-id-type="pmid">18156677</pub-id></element-citation></ref><ref id="B32-materials-13-05312"><label>32.</label><element-citation publication-type="book"><source>CrysAlisPro, Version 1.171.38.43 Package of Programs, Rigaku OD</source><publisher-name>Agilent Technologies Ltd.</publisher-name><publisher-loc>Yarnton, UK</publisher-loc><year>2015</year></element-citation></ref><ref id="B33-materials-13-05312"><label>33.</label><element-citation publication-type="web"><article-title>Cambridge Crystallographic Data Centre Home Page</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.ccdc.cam.ac.uk/structures">www.ccdc.cam.ac.uk/structures</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-11-20">(accessed on 20 November 2020)</date-in-citation></element-citation></ref><ref id="B34-materials-13-05312"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>A.</given-names></name></person-group><source>Selective Toxicity: The Physico-Chemical Basis of Therapy</source><publisher-name>Chapman and Hall</publisher-name><publisher-loc>London, UK</publisher-loc><year>1979</year><fpage>662</fpage><lpage>664</lpage></element-citation></ref><ref id="B35-materials-13-05312"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skehan</surname><given-names>P.</given-names></name><name><surname>Storeng</surname><given-names>R.</given-names></name><name><surname>Scudiero</surname><given-names>D.</given-names></name><name><surname>Monks</surname><given-names>A.</given-names></name><name><surname>McMahon</surname><given-names>J.</given-names></name><name><surname>Vistica</surname><given-names>D.</given-names></name><name><surname>Warren</surname><given-names>J.T.</given-names></name><name><surname>Bokesch</surname><given-names>H.</given-names></name><name><surname>Kenney</surname><given-names>S.</given-names></name><name><surname>Boyd</surname><given-names>M.R.</given-names></name></person-group><article-title>New colorimetric cytotoxicity assay for anticancer-drug screening</article-title><source>J. Natl. Cancer Inst.</source><year>1990</year><volume>82</volume><fpage>1107</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1093/jnci/82.13.1107</pub-id><?supplied-pmid 2359136?><pub-id pub-id-type="pmid">2359136</pub-id></element-citation></ref><ref id="B36-materials-13-05312"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L.</given-names></name><name><surname>Gou</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name></person-group><article-title>Platinum(II) complexes with N-monoalkyl 1R,2R-diaminocyclohenxane derivatives as carrier ligands and 3-hydroxycyclobutane- 1,1-dicarboxylate as a leaving group: Potent cytotoxicity and DNA binding ability</article-title><source>Eur. J. Med. Chem.</source><year>2013</year><volume>69</volume><fpage>842</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2013.07.004</pub-id><?supplied-pmid 24121235?><pub-id pub-id-type="pmid">24121235</pub-id></element-citation></ref><ref id="B37-materials-13-05312"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Gou</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name></person-group><article-title>Antitumor platinum(II) complexes of N-monoalkyl 1R,2R-diamino-cyclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as a leaving group</article-title><source>Eur. J. Med. Chem.</source><year>2014</year><volume>85</volume><fpage>408</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.08.007</pub-id><?supplied-pmid 25108080?><pub-id pub-id-type="pmid">25108080</pub-id></element-citation></ref><ref id="B38-materials-13-05312"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Hoffmann</surname><given-names>K.</given-names></name><name><surname>Muzio&#x00142;</surname><given-names>T.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name></person-group><article-title>Multinuclear magnetic resonance and X-ray characterization of platinum(II) complexes with substituted-1,2,4-triazolo [1,5-<italic>a</italic>]pyrimidines</article-title><source>J. Mol. Struct.</source><year>2014</year><volume>1056</volume><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2013.10.021</pub-id></element-citation></ref><ref id="B39-materials-13-05312"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Fandzloch</surname><given-names>M.</given-names></name><name><surname>Muzio&#x00142;</surname><given-names>T.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name><name><surname>Wietrzyk</surname><given-names>J.</given-names></name></person-group><article-title>Structure-cytotoxicity relationship for different types of mononuclear platinum(II) complexes with 5,7-di<italic>tert</italic>butyl-1,2,4- triazolo[1,5-<italic>a</italic>]pyrimidine</article-title><source>J. Inorg. Biochem.</source><year>2012</year><volume>115</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2012.05.005</pub-id><pub-id pub-id-type="pmid">22926029</pub-id></element-citation></ref><ref id="B40-materials-13-05312"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Fandzloch</surname><given-names>M.</given-names></name><name><surname>Pop&#x00142;awska</surname><given-names>B.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name></person-group><article-title>Platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidines: Spectroscopical characterization and cytotoxic activity in vitro</article-title><source>Spectrochim. Acta Part A</source><year>2012</year><volume>91</volume><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.saa.2012.01.050</pub-id></element-citation></ref><ref id="B41-materials-13-05312"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>M.</given-names></name><name><surname>Lou</surname><given-names>L.</given-names></name><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-<italic>&#x003ba;</italic><sup>2</sup><italic>N</italic>,<italic>N</italic>&#x02032;] platinum(II) complexes</article-title><source>J. Inorg. Biochem.</source><year>2008</year><volume>102</volume><fpage>1942</fpage><lpage>1946</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2008.07.003</pub-id><pub-id pub-id-type="pmid">18707762</pub-id></element-citation></ref><ref id="B42-materials-13-05312"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Hou</surname><given-names>S.</given-names></name><name><surname>Quan</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Lou</surname><given-names>L.</given-names></name></person-group><article-title>Synthesis, anticancer activity and toxicity of a water-soluble <italic>4S,5S</italic>-derivative of heptaplatin, <italic>cis</italic>-{Pt(II)[(<italic>4S,5S</italic>)-4,5-bis(aminomethyl)-2-isopropyl- 1,3-dioxolane]&#x000b7;(3-hydroxyl-cyclobutane-1,1-dicarboxylate)}</article-title><source>J. Inorg. Biochem.</source><year>2014</year><volume>140</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2014.07.013</pub-id><pub-id pub-id-type="pmid">25108185</pub-id></element-citation></ref><ref id="B43-materials-13-05312"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>R.</given-names></name><name><surname>Gou</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title><italic>In vitro</italic> biological evaluation of platinum(II) complexes with 1-(methoxy substituted benzyl) azetidine-3,3-dicarboxylato ligands</article-title><source>Bioorg. Med. Chem.</source><year>2012</year><volume>20</volume><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.12.056</pub-id><pub-id pub-id-type="pmid">22264764</pub-id></element-citation></ref><ref id="B44-materials-13-05312"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Sz&#x00142;yk</surname><given-names>E.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name><name><surname>Kozerski</surname><given-names>L.</given-names></name><name><surname>Nasulewicz</surname><given-names>A.</given-names></name><name><surname>Pe&#x00142;czy&#x00144;ska</surname><given-names>M.</given-names></name><name><surname>Wietrzyk</surname><given-names>J.</given-names></name><name><surname>Opolski</surname><given-names>A.</given-names></name></person-group><article-title>Multinuclear NMR spectroscopy and antitumor activity of novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidines</article-title><source>J. Inorg. Biochem.</source><year>2004</year><volume>98</volume><fpage>167</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2003.09.001</pub-id><?supplied-pmid 14659646?><pub-id pub-id-type="pmid">14659646</pub-id></element-citation></ref><ref id="B45-materials-13-05312"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sz&#x00142;yk</surname><given-names>E.</given-names></name><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Surdykowski</surname><given-names>A.</given-names></name><name><surname>G&#x00142;owiak</surname><given-names>T.</given-names></name><name><surname>Pazderski</surname><given-names>L.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name><name><surname>Kozerski</surname><given-names>L.</given-names></name></person-group><article-title>The X-ray structure and spectroscopy of platinum(II) complexes with 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidines and dimethylsulfoxide</article-title><source>Inorg. Chim. Acta</source><year>2002</year><volume>333</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/S0020-1693(02)00771-5</pub-id></element-citation></ref><ref id="B46-materials-13-05312"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Barwio&#x00142;ek</surname><given-names>M.</given-names></name><name><surname>Wojtczak</surname><given-names>A.</given-names></name><name><surname>Sz&#x00142;yk</surname><given-names>E.</given-names></name></person-group><article-title>X-ray structure and multinuclear NMR studies of platinum(II) and palladium(II) complexes with 5,7-di<italic>tert</italic>butyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine</article-title><source>Polyhedron</source><year>2007</year><volume>26</volume><fpage>5349</fpage><lpage>5355</lpage><pub-id pub-id-type="doi">10.1016/j.poly.2007.08.003</pub-id></element-citation></ref><ref id="B47-materials-13-05312"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>O.</given-names></name><name><surname>Roszak</surname><given-names>A.W.</given-names></name><name><surname>Buncel</surname><given-names>E.</given-names></name></person-group><article-title>Synthesis, characterization and x-ray crystal structure determination of platinum(II)-diaminoalkane complexes</article-title><source>Inorg. Chim. Acta</source><year>1996</year><volume>253</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/S0020-1693(96)05109-2</pub-id></element-citation></ref><ref id="B48-materials-13-05312"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornia</surname><given-names>A.</given-names></name></person-group><article-title>The bonding of thiazoles to platinum(II) complexes. X-ray crystal structure of <italic>cis</italic>- and <italic>trans</italic>-[Pt(dimethyl sulfoxide)(thiazole)Cl<sub>2</sub>]</article-title><source>Inorg. Chim. Acta</source><year>1997</year><volume>255</volume><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/S0020-1693(96)05391-1</pub-id></element-citation></ref><ref id="B49-materials-13-05312"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Almeida</surname><given-names>S.G.</given-names></name><name><surname>Hubbard</surname><given-names>J.L.</given-names></name><name><surname>Farrell</surname><given-names>N.</given-names></name></person-group><article-title>Spectroscopic and structural properties of dimethyl-, diphenyl- and methylphenylsulfoxide platinum complexes. The crystal and molecular structures of <italic>cis</italic>-dichlorobis(methylphenylsulfoxide)-platinum(II) and potassiumtrichloro(phenylsulfoxide)- platinum(II)acetone solvate</article-title><source>Inorg. Chim. Acta</source><year>1992</year><volume>193</volume><fpage>149</fpage><lpage>157</lpage></element-citation></ref><ref id="B50-materials-13-05312"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calligaris</surname><given-names>M.</given-names></name></person-group><article-title>Structure and bonding in metal sulfoxide complexes: An update</article-title><source>Coord. Chem. Rev.</source><year>2004</year><volume>248</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.02.005</pub-id></element-citation></ref><ref id="B51-materials-13-05312"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;akomska</surname><given-names>I.</given-names></name><name><surname>Babinska</surname><given-names>M.</given-names></name><name><surname>Wojtczak</surname><given-names>A.</given-names></name><name><surname>Sitkowski</surname><given-names>J.</given-names></name></person-group><article-title>Synthesis, characterization and <italic>in vitro</italic> cytotoxicity of three types of platinum(II) complexes containing 5,7-diethyl-1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidine</article-title><source>Inorg. Chim. Acta</source><year>2016</year><volume>453</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.ica.2016.09.010</pub-id></element-citation></ref><ref id="B52-materials-13-05312"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu&#x000df;</surname><given-names>I.</given-names></name><name><surname>Garmann</surname><given-names>D.</given-names></name><name><surname>Galanski</surname><given-names>M.</given-names></name><name><surname>Weber</surname><given-names>G.</given-names></name><name><surname>Kalayda</surname><given-names>G.V.</given-names></name><name><surname>Keppler</surname><given-names>B.K.</given-names></name><name><surname>Jaehde</surname><given-names>U.</given-names></name></person-group><article-title>Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?</article-title><source>J. Inorg. Biochem.</source><year>2011</year><volume>105</volume><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2011.02.005</pub-id><pub-id pub-id-type="pmid">21450275</pub-id></element-citation></ref><ref id="B53-materials-13-05312"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margiotta</surname><given-names>N.</given-names></name><name><surname>Marzano</surname><given-names>C.</given-names></name><name><surname>Gandin</surname><given-names>V.</given-names></name><name><surname>Osella</surname><given-names>D.</given-names></name><name><surname>Ravera</surname><given-names>M.</given-names></name><name><surname>Gabano</surname><given-names>E.</given-names></name><name><surname>Platts</surname><given-names>J.A.</given-names></name><name><surname>Petruzzella</surname><given-names>E.</given-names></name><name><surname>Hoeschele</surname><given-names>J.D.</given-names></name><name><surname>Natile</surname><given-names>G.</given-names></name></person-group><article-title>Revisiting [PtCl<sub>2</sub>(<italic>cis</italic>-1,4-DACH)]: An Underestimated Antitumor Drug with Potential Application to the Treatment of Oxaliplatin-Refractory Colorectal Cancer</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><fpage>7182</fpage><lpage>7192</lpage><pub-id pub-id-type="doi">10.1021/jm3006838</pub-id><pub-id pub-id-type="pmid">22788918</pub-id></element-citation></ref><ref id="B54-materials-13-05312"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platts</surname><given-names>J.A.</given-names></name><name><surname>Oldfield</surname><given-names>S.P.</given-names></name><name><surname>Reif</surname><given-names>M.M.</given-names></name><name><surname>Palmucci</surname><given-names>A.</given-names></name><name><surname>Gabano</surname><given-names>E.</given-names></name></person-group><article-title>The RP-HPLC measurement and QSPR analysis of logPo/w values of several Pt(II) complexes</article-title><source>J. Inorg. Biochem.</source><year>2006</year><volume>100</volume><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2006.01.035</pub-id><?supplied-pmid 16530269?><pub-id pub-id-type="pmid">16530269</pub-id></element-citation></ref><ref id="B55-materials-13-05312"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q.S.</given-names></name><name><surname>Lou</surname><given-names>L.G.</given-names></name><name><surname>Liu</surname><given-names>W.P.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.Z.</given-names></name><name><surname>Hou</surname><given-names>S.Q.</given-names></name><name><surname>Gao</surname><given-names>W.Q.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Synthesis and <italic>in vitro</italic> cytotoxicity of novel lipophilic (diamine)platinum(II) complexes of salicylate derivatives</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2007</year><volume>17</volume><fpage>2146</fpage><lpage>2149</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2007.01.084</pub-id><?supplied-pmid 17306532?><pub-id pub-id-type="pmid">17306532</pub-id></element-citation></ref><ref id="B56-materials-13-05312"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldfield</surname><given-names>S.P.</given-names></name><name><surname>Hall</surname><given-names>M.D.</given-names></name><name><surname>Platts</surname><given-names>J.A.</given-names></name></person-group><article-title>Calculation of Lipophilicity of a Large, Diverse Dataset of Anticancer Platinum Complexes and the Relation to Cellular Uptake</article-title><source>J. Med. Chem.</source><year>2007</year><volume>50</volume><fpage>5227</fpage><lpage>5237</lpage><pub-id pub-id-type="doi">10.1021/jm0708275</pub-id><?supplied-pmid 17900102?><pub-id pub-id-type="pmid">17900102</pub-id></element-citation></ref><ref id="B57-materials-13-05312"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sava</surname><given-names>G.</given-names></name><name><surname>Jaouen</surname><given-names>G.</given-names></name><name><surname>Hillard</surname><given-names>E.A.</given-names></name><name><surname>Bergamo</surname><given-names>A.</given-names></name></person-group><article-title>Targeted therapy <italic>vs.</italic> DNA-adduct formation-guided design: Thoughts about the future of metal-based anticancer drugs</article-title><source>Dalton Trans.</source><year>2012</year><volume>41</volume><fpage>8226</fpage><lpage>8234</lpage><?supplied-pmid 22614531?><pub-id pub-id-type="pmid">22614531</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="materials-13-05312-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Synthesis pathways of platinum(II) complexes with 1,2,4-triazolo[1,5-<italic>a</italic>]pyrimidines.</p></caption><graphic xlink:href="materials-13-05312-g001"/></fig><fig id="materials-13-05312-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><sup>195</sup>Pt NMR data for different types of chromophore systems.</p></caption><graphic xlink:href="materials-13-05312-g002"/></fig><fig id="materials-13-05312-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>X-ray crystal structure of (<bold>5</bold>) [Pt(mal)(DMSO)(dmtp)] with selected bond lengths (&#x000c5;) and angles (&#x000b0;).</p></caption><graphic xlink:href="materials-13-05312-g003"/></fig><fig id="materials-13-05312-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Lipophilicity of platinum(II) complexes.</p></caption><graphic xlink:href="materials-13-05312-g004"/></fig><fig id="materials-13-05312-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Influences of carrier ligand and leaving group on in vitro cytotoxicity.</p></caption><graphic xlink:href="materials-13-05312-g005"/></fig><table-wrap id="materials-13-05312-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">materials-13-05312-t001_Table 1</object-id><label>Table 1</label><caption><p>Crystal data and structure refinement for (<bold>5</bold>) [Pt(mal)(DMSO)(dmtp)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Result</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Empirical formula</td><td align="center" valign="middle" rowspan="1" colspan="1">C<sub>12</sub>H<sub>16</sub>N<sub>4</sub>O<sub>5</sub>PtS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Formula weight</td><td align="center" valign="middle" rowspan="1" colspan="1">523.44</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Temperature; K</td><td align="center" valign="middle" rowspan="1" colspan="1">293(2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Wavelength; &#x000c5;</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71073</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Crystal system</td><td align="center" valign="middle" rowspan="1" colspan="1">Orthorhombic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Space group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pbca</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Unit cell dimensions; &#x000c5;,</td><td align="center" valign="middle" rowspan="1" colspan="1">a = 11.7627(4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">b = 8.8447(3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">c = 30.8525(11)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b2;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Volume; &#x000c5;<sup>3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3209.82(19)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Z</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Density (calculated); Mg/m<sup>3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">2.166</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Absorption coefficient; mm<sup>&#x02212;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">8.903</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">F(000)</td><td align="center" valign="middle" rowspan="1" colspan="1">2000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Crystal size; mm</td><td align="center" valign="middle" rowspan="1" colspan="1">0.331 &#x000d7; 0.217 &#x000d7; 0.022</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Theta range for data collection</td><td align="center" valign="middle" rowspan="1" colspan="1">2.177 to 28.678&#x000b0;.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Index ranges</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;10 &#x02264; h &#x02264; 15, &#x02212;11 &#x02264; k &#x02264; 11, &#x02212;34 &#x02264; l &#x02264; 38</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Reflections collected</td><td align="center" valign="middle" rowspan="1" colspan="1">20604</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Independent reflections</td><td align="center" valign="middle" rowspan="1" colspan="1">3785 [R(int) = 0.0540]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Completeness to theta</td><td align="center" valign="middle" rowspan="1" colspan="1">25.242&#x000b0;, 99.8%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Absorption correction</td><td align="center" valign="middle" rowspan="1" colspan="1">Analytical</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Max. and min. transmission</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8291 and 0.1618</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Refinement method</td><td align="center" valign="middle" rowspan="1" colspan="1">Full-matrix least-squares on F<sup>2</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Data/restraints/parameters</td><td align="center" valign="middle" rowspan="1" colspan="1">3785/0/208</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Goodness-of-fit on F<sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.060</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Final R indices [I &#x0003e; 2sigma(I)]</td><td align="center" valign="middle" rowspan="1" colspan="1">R1 = 0.0395, wR2 = 0.0760</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">R indices (all data)</td><td align="center" valign="middle" rowspan="1" colspan="1">R1 = 0.0601, wR2 = 0.0802</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Largest diff. peak and hole; e.&#x000c5;<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.06 d &#x02212;3.949</td></tr></tbody></table></table-wrap><table-wrap id="materials-13-05312-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">materials-13-05312-t002_Table 2</object-id><label>Table 2</label><caption><p><sup>1</sup>H and <sup>15</sup>N NMR chemical shifts (&#x003b4;) of platinum(II) complexes [in ppm].</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Compounds</th><th colspan="2" align="center" valign="top" style="border-top:solid thin" rowspan="1"><sup>1</sup>H</th><th colspan="4" align="center" valign="top" style="border-top:solid thin" rowspan="1"><sup>15</sup>N</th></tr><tr><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">H(2)</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">H(6)</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">N(1)</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">N(3)</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">N(4)</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">N(8)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>1</bold>) [Pt(mal)(dbtp)(DMSO)]</td><td align="center" valign="top" rowspan="1" colspan="1">9.19 (+0.39)</td><td align="center" valign="top" rowspan="1" colspan="1">7.55 (+0.24)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;105.8 (&#x02212;0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;252.5 (&#x02212;86.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;121.6 (&#x02212;5.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;160.2 (&#x02212;3.7) </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>2</bold>) [Pt(mal)(DMSO)(ibmtp)]</td><td align="center" valign="top" rowspan="1" colspan="1">9.15 (+0.73)</td><td align="center" valign="top" rowspan="1" colspan="1">7.59 (+0.22)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;110.3 (&#x02212;4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;252.1 (&#x02212;62.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;120.1 (&#x02212;6.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;158.3 (&#x02212;1.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)]</td><td align="center" valign="top" rowspan="1" colspan="1">9.21 (+0.41)</td><td align="center" valign="top" rowspan="1" colspan="1">7.55 (+0.24)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;106.0 (&#x02212;0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;253.0 (&#x02212;85.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;122.0 (&#x02212;4.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;161.0 (&#x02212;2.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>4</bold>) [Pt(CBDC)(DMSO)(ibmtp)]</td><td align="center" valign="top" rowspan="1" colspan="1">9.16 (+0.74)</td><td align="center" valign="top" rowspan="1" colspan="1">7.58 (+0.21)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;110.3 (&#x02212;4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;251.7 (&#x02212;87.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;119.8 (&#x02212;6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;158.3 (&#x02212;1.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(<bold>5</bold>) [Pt(mal)(DMSO)(dmtp)] [<xref rid="B25-materials-13-05312" ref-type="bibr">25</xref>]</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">9.14 (+0.55)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">7.58 (+0.39)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;109.7 (+2.2)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;252.2 (&#x02212;98.3)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;120.8 (&#x02212;5.0)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;157.4 (&#x02212;2.1)</td></tr></tbody></table></table-wrap><table-wrap id="materials-13-05312-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">materials-13-05312-t003_Table 3</object-id><label>Table 3</label><caption><p><sup>13</sup>C and <sup>195</sup>Pt NMR chemical shifts (&#x003b4;) of platinum(II) complexes [in ppm].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C(2)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C(3a)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C(5)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C(6)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C(7)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pt</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>1</bold>) [Pt(mal)(dbtp)(DMSO)]</td><td align="center" valign="top" rowspan="1" colspan="1">152.8 (&#x02212;0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">152.6 (&#x02212;4.1)</td><td align="center" valign="top" rowspan="1" colspan="1">179.8 (+3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">107.9 (+3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">159.3 (+1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2609 (&#x02212;985)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>2</bold>) [Pt(mal)(DMSO)(ibmtp)]</td><td align="center" valign="top" rowspan="1" colspan="1">153.2 (+2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">152.3 (&#x02212;4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">169.5 (+0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">114.3 (+0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">151.9 (+0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2598 (&#x02212;974)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)]</td><td align="center" valign="top" rowspan="1" colspan="1">153.0 (+0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">152.7 (&#x02212;4.2)</td><td align="center" valign="top" rowspan="1" colspan="1">179.7 (+3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">107.0 (+4.2)</td><td align="center" valign="top" rowspan="1" colspan="1">159.0 (+1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2607 (&#x02212;983)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(<bold>4</bold>) [Pt(CBDC)(DMSO)(ibmtp)]</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">153.4 (+1.8)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">152.3 (&#x02212;4.6)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">169.4 (+0.3)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">114.2 (+1.0)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">151.9 (+0.7)</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2605 (&#x02212;981)</td></tr></tbody></table></table-wrap><table-wrap id="materials-13-05312-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">materials-13-05312-t004_Table 4</object-id><label>Table 4</label><caption><p>IR spectroscopic data for platinum(II) complexes (in cm<sup>&#x02212;1</sup>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003bd;<sub>as(OCO</sub>&#x02014;<sub>)</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003bd;<sub>pyrim. ring</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003bd;<sub>triazole ring</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003bd;<sub>sym(OCO</sub>&#x02014;<sub>)</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;&#x02019;</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>1</bold>) [Pt(mal)(dbtp)(DMSO)]</td><td align="center" valign="top" rowspan="1" colspan="1">1662</td><td align="center" valign="top" rowspan="1" colspan="1">1617</td><td align="center" valign="top" rowspan="1" colspan="1">1541</td><td align="center" valign="top" rowspan="1" colspan="1">1344</td><td align="center" valign="top" rowspan="1" colspan="1">318</td><td rowspan="2" align="center" valign="middle" colspan="1">197</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>2</bold>) [Pt(mal)(DMSO)(ibmtp)]</td><td align="center" valign="top" rowspan="1" colspan="1">1662</td><td align="center" valign="top" rowspan="1" colspan="1">1636</td><td align="center" valign="top" rowspan="1" colspan="1">1555</td><td align="center" valign="top" rowspan="1" colspan="1">1351</td><td align="center" valign="top" rowspan="1" colspan="1">311</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)]</td><td align="center" valign="top" rowspan="1" colspan="1">1656</td><td align="center" valign="top" rowspan="1" colspan="1">1618</td><td align="center" valign="top" rowspan="1" colspan="1">1542</td><td align="center" valign="top" rowspan="1" colspan="1">1339</td><td align="center" valign="top" rowspan="1" colspan="1">317</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">268</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(<bold>4</bold>) [Pt(CBDC)(DMSO)(ibmtp)]</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1669</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1636</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1555</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1341</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">328</td></tr></tbody></table></table-wrap><table-wrap id="materials-13-05312-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">materials-13-05312-t005_Table 5</object-id><label>Table 5</label><caption><p>In vitro antiproliferative activity of platinum(II) complexes (in &#x000b5;M).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Compounds</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin" rowspan="1">IC<sub>50</sub>
<sup>a</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A549</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LoVo</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T47D</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/3T3</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>1</bold>) [Pt(mal)(dbtp)(DMSO)]</td><td align="center" valign="middle" rowspan="1" colspan="1">16.28 &#x000b1; 9.9</td><td align="center" valign="middle" rowspan="1" colspan="1">27.92 &#x000b1; 1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">17.07 &#x000b1; 10.5</td><td align="center" valign="middle" rowspan="1" colspan="1">30.25 &#x000b1; 22.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>2</bold>) [Pt(mal)(DMSO)(ibmtp)]</td><td align="center" valign="middle" rowspan="1" colspan="1">57.81 &#x000b1; 13.5</td><td align="center" valign="middle" rowspan="1" colspan="1">38.35 &#x000b1; 1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">42.6 &#x000b1; 19.0</td><td align="center" valign="middle" rowspan="1" colspan="1">45.95 &#x000b1; 40.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>3</bold>) [Pt(CBDC)(dbtp)(DMSO)]</td><td align="center" valign="middle" rowspan="1" colspan="1">5.00 &#x000b1; 0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">20.02 &#x000b1; 2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">6.60 &#x000b1; 4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">10.19 &#x000b1; 6.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(<bold>4</bold>) [Pt(CBDC)(DMSO)(ibmtp)]</td><td align="center" valign="middle" rowspan="1" colspan="1">57.29 &#x000b1; 11.3</td><td align="center" valign="middle" rowspan="1" colspan="1">41.19 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">21.87 &#x000b1; 17.2</td><td align="center" valign="middle" rowspan="1" colspan="1">73.40 &#x000b1; 29.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.00 &#x000b1; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.11 &#x000b1; 1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.20 &#x000b1; 1.5</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> The values are averages of three independent determinations.</p></fn></table-wrap-foot></table-wrap></floats-group></article>